



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Supervised injecting room cohort study (SIRX): study protocol

| | |
|-------------------------------|--|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2024-091337 |
| Article Type: | Protocol |
| Date Submitted by the Author: | 18-Jul-2024 |
| Complete List of Authors: | <p>Stewart, Ashleigh; Burnet Institute, Behaviours and Health Risks; Monash University, School of Public Health and Preventive Medicine Hickman, Matthew; University of Bristol, Population Health Sciences Agius, Paul A.; Burnet Institute; Deakin University Faculty of Health Scott, Nick; Burnet Institute; Monash University, School of Public Health and Preventive Medicine Stone, Jack ; University of Bristol, Population Health Sciences Roxburgh, Amanda; Burnet Institute; Monash University, School of Public Health and Preventive Medicine O'Keefe, Daniel; Burnet Institute; Monash University, School of Public Health and Preventive Medicine Higgs, Peter; Burnet Institute, Behaviours and Health Risks; La Trobe University, Public Health Kerr, Thomas; The University of British Columbia Department of Medicine, Division of Social Medicine; British Columbia Centre on Substance Use Stoové, Mark; Burnet Institute; Monash University, School of Public Health and Preventive Medicine Thompson, Alexander; St Vincent's Hospital Melbourne, Department of Gastroenterology; The University of Melbourne, Department of Medicine Crawford, S; Harm Reduction Victoria Norman, Josephine; Department of Health Victoria, Centre for Evaluation and Research Evidence Vella-Horne, Dylan; Burnet Institute, Behaviours and Health Risks Lloyd, Zachary ; Burnet Institute, Behaviours and Health Risks Clark, Nico; Burnet Institute, Behaviours and Health Risks Maher, Lisa; The Kirby Institute Dietze, Paul; Burnet Institute; National Drug Research Institute</p> |
| Keywords: | Drug Utilization, Health Services, Substance misuse < PSYCHIATRY |
| | |

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Title page

Supervised injecting room cohort study (SIRX): study protocol

Authors: Stewart AC^{1,2}, Hickman M³, Agius PA^{1,4}, Scott N^{1,2}, Stone J³, Roxburgh A^{1,2}, O’Keefe D^{1,2}, Higgs P^{1,6}, Kerr T^{7,8}, Stoové M^{1,2}, Thompson A^{9,10}, Crawford S¹¹, Norman J¹², Vella-Horne D¹, Lloyd Z¹, Clark N¹, Maher L^{1,13}Dietze PM^{1,2,5}

Corresponding Author: Ashleigh Stewart – Ashleigh.stewart@burnet.edu.au

Author emails:

1. Matthew.Hickman@bristol.ac.uk
2. p.agius@deakin.edu.au
3. nick.scott@burnet.edu.au
4. j.stone@bristol.ac.uk
5. Amanda.Roxburgh@burnet.edu.au
6. daniel.okeefe@burnet.edu.au
7. peter.higgs@burnet.edu.au
8. thomas.kerr@bccsu.ubc.ca
9. mark.stoove@burnet.edu.au
10. alexander.thompson@svha.org.au
11. sionec@hrvic.org.au
12. Josephine.Norman@health.vic.gov.au
13. dylan.vella-horne@burnet.edu.au
14. zachary.lloyd@burnet.edu.au
15. nico.clark@gmail.com
16. Lmaher@kirby.unsw.edu.au
17. Paul.dietze@burnet.edu.au

Affiliations:

1. Disease Elimination, Burnet Institute, Melbourne, Australia
2. School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
3. Population Health Sciences, Bristol Medical School, University of Bristol, UK
4. Faculty of Health, Deakin University, Melbourne, Australia
5. National Drug Research Institute, Curtin University, Melbourne, Australia
6. School of Public Health, La Trobe University, Melbourne, Australia
7. Division of Social Medicine, Department of Medicine, University of British Columbia
8. Director of Research/Senior Scientist, British Columbia Centre on Substance Use
9. Department of Gastroenterology, St Vincent’s Hospital Melbourne, Melbourne, VIC, Australia
10. Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia
11. Harm Reduction Victoria, Melbourne, Victoria, Australia
12. Centre for Evaluation and Research Evidence, Department of Health, Victoria, Australia
13. Kirby Institute, Faculty of Medicine, UNSW Sydney

Word count: 4259

Key words: Injecting drug use, people who inject drugs, supervised injecting facility, drug consumption room, safe injection, cohort study, administrative data linkage

Competing interests:

PH and MS has received investigator-driven research funding from Gilead Sciences and Abbvie for work on hepatitis C, unrelated to this manuscript. AT Advisory board member – Abbvie, Gilead Sciences, Roche Diagnostics, BMS, Assembly Biosciences, Immunocore; Speaker – Abbvie, Gilead Sciences, Roche Diagnostics, Roche, BMS; Research/grant support – Gilead Sciences, Abbvie, Roche Diagnostics. SC has received funding from Camurus and HRVic has received funding from Indivior. JS was involved in the two reviews of the MSIR as a salaried staff member of the Department of Health.

For peer review only

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Background

Supervised injecting facilities (SIFs) are designed to reduce the harms associated with injecting drug use. The Supervised Injecting Room Cohort Study (SIRX) aims to provide new evidence of the effectiveness, including cost-effectiveness, of SIFs through the development and maintenance of a sustained evaluation platform of the Melbourne Medically Supervised Injecting Room (MSIR).

Methods and analysis

The overall SIRX design involves two prospective cohort studies through which key behavioural data are retrospectively and prospectively linked to administrative primary and tertiary health service databases, criminal justice records, and mortality data. The two cohorts are: 1) participants drawn from the existing Melbourne Injecting Drug User Cohort Study (SuperMIX; established in 2008–ongoing) through which participants consent to annual behavioural surveys (including serological testing for HIV and hepatitis B and C virus) and linkage to administrative health records; and 2) a SIRX-Registration Cohort (SIRX-R; established in 2023) comprising registered MSIR clients who consent to a baseline behavioural survey and administrative data linkage including their SIF use. The SuperMIX Cohort component will include participants for whom MSIR use may vary across time (i.e., those who might never use, those who alternate between use and non-use and those that consistently use). Aligned to the legislated aims of the MSIR, primary outcome analyses will estimate the effect of MSIR exposure (frequent use/infrequent use/no use) on ambulance attended non-fatal overdoses and all-cause and drug-related mortality, using causal inference methods. The SIRX study also has a secondary focus on the effect of MSIR exposure on health service use and related outcomes.

Conclusion

Findings from the SIRX Study will assess the effectiveness of the Melbourne-based SIF in reducing drug-related harms, including non-fatal and fatal overdose, and facilitating other service engagement opportunities. Linking MSIR clients with their administrative health records provides robust measurements of the impact of the facility over time.

Ethics and dissemination

SuperMIX Study (599/21) and SIRX-R Study (71/23) ethics approvals were obtained from Alfred Hospital Research Ethics Committee. Participants will be assessed for capacity to provide informed consent following a detailed explanation of the study. Participants are informed of their right to withdraw from the study at any time and that withdrawing does not impact their access to services. Aggregated research results will be disseminated via presentations at national and international scientific conferences and publications in peer-reviewed journals. Local-level reports and outputs will be distributed to key study stakeholders and policymakers. Summary findings for participants will be displayed in relevant services and the study van, via accessible outputs (e.g., short infographics summaries).

Strengths and limitations of this study

- The Supervised Injecting Room Cohort Study (SIRX) uses a cohort and quasi-experimental design to measure varying levels of exposure to the Melbourne Medically Supervised Injecting Room (MSIR) and the effect of these exposure levels across a range of outcomes.
- Comprehensive longitudinal behavioural data and linkage to MSIR visits and routinely collected administrative health and social databases.
- The SuperMIX Cohort may be subject to attrition bias through lost-to-follow-up, however, data linkage for primary outcomes minimises this risk.
- Consistent with all observational studies, confounding may impact the observed associations, but causal inference methods are being applied to minimise this.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Background

Regular injecting drug use is associated with a wide range of adverse health outcomes including drug overdose deaths, which have steadily increased in the last two decades in Australia and globally.^{1, 2} Injecting-related harms also include blood-borne viral infections (e.g., HIV, viral hepatitis) and injection-related injuries and infections (e.g., skin, soft tissue injuries and endocarditis),^{1, 3} all of which are key drivers of morbidity, mortality, as well as drug-related economic costs to the community.^{4, 5} Injecting drug use is also connected to wider social and economic harms, including drug-related crime⁶ and avoidable healthcare costs.^{7, 8}

Social marginalisation, stigma, and trauma are driven by myriad factors including adverse childhood experiences,^{9, 10} unemployment,¹¹ persistent housing instability,^{12, 13} and imprisonment^{3, 14, 15} and compound the risks among people who inject drugs.^{16, 17} Stigma and discrimination, in particular, contributes to suboptimal health care, undermining access to supportive services, such as opioid agonist therapy (OAT).¹⁸ Further, harms created by structural barriers and social exclusion can cause delays in seeking care, which may lead to frequent use of acute care services such as hospital emergency departments (ED).¹⁹

Harm reduction interventions, including needle and syringe programs (NSPs) and OAT, have been shown to be effective at reducing injecting-related harm²⁰ and health service use²¹ but suboptimal program coverage is common in Australia and internationally.²² Further, NSPs and OAT do not provide an immediate response to acute harms, such as drug overdoses and the costs associated with managing them.

Supervised injecting facilities

Supervised injecting facilities* (SIFs) were first established in Europe in the mid-1980s in response to epidemics of public injecting, overdose, and increasing HIV incidence related to injection drug use.²³ SIFs, and drug consumption rooms more broadly, provide an environment where individuals can use pre-obtained drugs with sterile equipment under supervision. SIFs provide an emergency response in the event of drug overdose and often facilitate referrals to health and social services, which evidence shows is associated with increases in drug treatment uptake.²⁴ As of 2023, SIFs were legally operating in 17 (predominantly high income) countries.²²

Evidence from observational, modelling, ecological, and qualitative studies demonstrates that SIFs reduce a range of harms, including drug-related²⁵⁻²⁷ and all-cause mortality,²⁸ ambulance attendances for drug overdose,²⁹ and ED presentations.³⁰ Evidence also suggests SIFs are associated with reductions in experiencing violence,^{31, 32} receptive needle and syringe sharing,³³ and HIV incidence.³⁴ Further, SIFs have demonstrated effectiveness in attracting individuals at greatest risk of harm, such as those experiencing homelessness, mental illness, people who inject in public spaces and people who engage in high-risk drug use.³⁵⁻³⁷ SIFs have had a documented positive impact on public amenity by reducing public injecting and ensuring safe disposal of injecting equipment.^{38, 39}

* Many labels are used to describe supervised drug consumption sites and overdose prevention centres. As this article is focused on facilities that only permit drug injecting under supervision, the term ‘supervised injecting facility’ is used throughout the article.

Thus, SIFs demonstrate utility in offering a range of harm reduction services and referrals to populations considered to be experiencing social and structural vulnerability.

Despite this evidence base, the evaluation of SIFs remains challenging with researchers determining randomised control trials to be unethical for evaluating the effect of SIFs, particularly in the absence of clinical equipoise when intervening in the event of an overdose.^{40, 41} Thus, past evaluations have relied exclusively on observational data, which creates methodological challenges and when considering hierarchies of evidence. Further, the vast majority of international evidence in a recent review (16/22, studies, 72%) relates to a single SIF in Vancouver, Canada (Insite),⁴² itself a unique risk environment for drug related harm characterised by epidemics of HIV infection and overdose.⁴³ Thus, there remains an ongoing need to evaluate the impacts of SIFs with many unanswered questions, as well as a need to evaluate SIFs operating in other international contexts, with different operational models, and varying drug markets, patterns of drug use and epidemiological environments. For example, previous SIF cost effectiveness studies are focused on reductions in HIV incidence, which is of limited relevance to jurisdictions such as Australia where HIV remains rare among people who inject drugs.^{44, 45}

The Melbourne Medically Supervised Injecting Room (MSIR)

The Melbourne Medically Supervised Injecting Room (MSIR) was established in 2018, in North Richmond, an inner-city suburb of Melbourne with an established street drug market.⁴⁶ The North Richmond MSIR is located in the grounds of the largest public housing estate in Australia, directly adjacent to the North Richmond Community Health Centre. Within the first 18 months of operation, approximately 4000 clients registered to use the MSIR, with the facility averaging 300 visits per day following the opening of the purpose-built facility.⁴⁷

In 2020, a MSIR service review assessed the facility against its legislated objectives to: i) reduce avoidable deaths caused by drug overdose; ii) advance delivery of effective health services to MSIR clients; iii) reduce attendance and use of emergency and hospital services for drug overdose; iv) reduce discarded needles in public places and public injecting; v) improve neighbourhood amenity; and vi) reduce blood borne virus transmission.⁴⁷ Based on two reviews in 2020 and 2023, noted reductions in preventable deaths (including management of almost 6000 overdose events) and use of emergency services for overdose, and improvements in public amenity were observed.^{47, 48} Thus, the Government extended the MSIR operating license for three years and recommended the establishment of a second facility in the Melbourne Central Business District.⁴⁹ In 2024, the commitment to establish the second facility was withdrawn.⁵⁰

Despite these MSIR facility reviews demonstrating reductions for each of the facility-specific legislated aims, data used to generate these estimates were limited by small sample sizes of MSIR clients, coupled with a short evaluation timeframe that reduced analytical power. The withdrawal of the commitment to establish a second facility highlights the precarious situation of SIFs and the need for robust evidence on the effectiveness of SIFs, particularly in light of suggestions by the Victorian opposition that they would close the MSIR if elected.⁵¹ To this effect the SIRX study is designed as a large-sample longitudinal cohort design to provide the strongest possible evidence of the effectiveness of the MSIR. This protocol paper describes our approach to evaluating the impacts of the Melbourne-based SIF, focused on the facility's legislated aims (outlined below) related to

1
2
3 expected reductions in fatal and non-fatal overdose using comprehensive longitudinal data from two
4 cohort studies of people who inject drugs.
5

6
7 *The Melbourne Injecting Drug Use Cohort Study (SuperMIX)*
8

9
10 Data from The Melbourne Injecting Drug User Cohort Study (SuperMIX) were used to inform part of
11 the MSIR facility reviews. SuperMIX is the largest, only active, and longest running longitudinal study
12 of people who inject drugs in Australia and one of the largest internationally (N>1500 enrolled
13 participants).¹⁴ Established in 2008, SuperMIX involves annual interviews collecting detailed data on
14 drug use and risk behaviours, drug purchasing, health service and drug treatment utilisation, health
15 and well-being, and imprisonment. These detailed data are complemented by serological testing for
16 HIV and viral hepatitis, and linkage to the National Death Index (NDI), national Medical and
17 Pharmaceutical Benefits Schemes (MBS, PBS), state-wide emergency department presentations and
18 hospitalisations, ambulance attendances, and drug treatment contacts.¹⁴
19

20
21
22 Following the MSIR opening, SuperMIX participants were asked about their level and frequency of
23 exposure to the MSIR, annually. As part of the MSIR facility review, SuperMIX findings demonstrated
24 that MSIR clients were more likely to identify as Aboriginal and/or Torres Strait Islander, report
25 recent arrest, and report heroin as their main drug of choice.⁴⁷ SuperMIX participants previously
26 reporting injecting in high-risk settings, such as in public, were almost twice as likely to visit the MSIR
27 compared to participants not injecting in these settings. The MSIR review also found MSIR use was
28 associated with lower rates of ambulance attendance and naloxone administration, but these
29 findings were drawn from small samples or limited ecological data.⁴⁷
30

31
32
33 The current study will leverage the existing infrastructure of SuperMIX, particularly the study's
34 established relationships with people who inject drugs and the MSIR service.
35

36
37 *The current study*
38

39
40 The Supervised Injecting Room Cohort Study (SIRX) involves a breadth of longitudinal data obtained
41 linked to administrative health and social databases. With annually measured SuperMIX prospective
42 cohort data linked via MSIR facility registration, SIRX presents the opportunity to implement a quasi-
43 experimental study design permitting estimation of the causal effect of MSIR exposure using causal
44 inference methods. This study design was successfully applied in Vancouver,⁵² providing the
45 strongest evidence to date of SIF effectiveness.⁴² SIRX will broaden the evidence base for SIFs to
46 inform harm reduction responses to reduce injecting-related harms particularly in Australia given
47 opioid-related deaths have doubled since 2001.
48

49
50 SIRX aims to provide further evidence of the effectiveness, including cost-effectiveness, of SIFs by
51 estimating the total causal effect of MSIR use on all-cause and opioid related mortality and non-fatal
52 overdose. This study design will also allow for new evidence on additional secondary outcomes
53 related to SIF use such as self-reported public injecting, public syringe disposal, and receptive syringe
54 sharing, and enhanced hepatitis C treatment and health protective behaviours including vaccination
55 (e.g., COVID-19 and hepatitis B). It will also allow for a cost-effectiveness analysis to be undertaken
56 that combines a broader set of MSIR benefits, which have not previously been able to be quantified.
57

58
59
60 Aims

The primary aim of the SIRX study is to estimate longitudinal associations and any causal effects between MSIR use non-fatal overdose and mortality, and linked secondary aims are to examine similar effects on additional outcomes, including tertiary health service and drug treatment uptake. The study will also evaluate the cost effectiveness of the MSIR service in relation to these aims.

Methods

Study setting & design

The SIRX Study will be undertaken across Melbourne, Australia, with a particular focus on North Richmond, an inner suburb of Melbourne where the MSIR is located. The SIRX Study utilises a cohort and quasi-experimental design in which MSIR clients and people who inject drugs with varying levels of MSIR exposure are compared across a range of behavioural and linked administrative outcome data. Two cohorts will contribute to the SIRX Study, the SuperMIX Cohort and the SIRX-Registration (SIRX-R) Cohort (Figure 1).

Participant eligibility

MSIR clients will be eligible for the SIRX Study if they attend and use the MSIR in the six months prior to study contact and consent to an interview and record linkage. Currently, MSIR clients must be aged 18+ years and have initiated injecting drugs prior to MSIR registration and are neither on parole nor pregnant; SIRX Study eligibility will align with these requirements. Clients provide minimal information when registering and are given an anonymous client number, allowing for internal tracking on an MSIR database.

Study recruitment

A total of 3,000 registered MSIR clients will be recruited into the SIRX Study. MSIR data show



Figure 1 Study design of the SIRX Study

1
2
3 approximately 3,600 individual clients access the MSIR every nine months, indicating the need to
4 recruit every second client to complete recruitment in the expected nine-month recruitment period.
5 Previous experience indicates high response rates using these methods.⁵² Recruitment inside the
6 MSIR will be led by a cohort navigator who will work closely with research staff and MSIR staff to
7 facilitate participant recruitment.
8
9

10 SIRX Study enrolment and survey completion will occur post-injection either inside the MSIR or in a
11 research study van located outside the MSIR. Previous research demonstrates post-injection
12 interviews and testing is feasible at the North Richmond MSIR.^{53, 54} Researchers are trained to
13 monitor for signs of heavy intoxication and reschedule interviews in line with current research
14 standard operating protocols. Recruitment processes for SuperMIX and SIRX-R are detailed below.
15
16

17
18 *SuperMIX Cohort*
19

20 A total of 1200 registered MSIR clients will be recruited into the SuperMIX Cohort for annual surveys
21 and record linkage (including MSIR client records). This target recruitment sample consists of 360
22 participants already enrolled in SuperMIX and who report using the MSIR and approximately 840
23 new SuperMIX participants who are recruited directly from the MSIR. We will first consecutively
24 invite all MSIR clients to participate in SuperMIX until the target sample size is reached. Participants
25 recruited into SuperMIX will be reimbursed AUD\$40 for baseline and follow-up surveys and AUD\$10
26 for providing a blood-bio sample (total reimbursement AUD\$50).
27
28

29 The SuperMIX Cohort will also provide a study control group of people who inject drugs who do not
30 report using the MSIR (Figure 1).
31
32

33
34 *SIRX-R Cohort*
35

36 A total of 1800 participants will be recruited into the SIRX-R Cohort who will consent to record
37 linkage (including MSIR client records) and complete a once-off cross-sectional survey. To streamline
38 recruitment and reduce client burden, a SIRX Study data field will be added to the MSIR client
39 database to identify clients who are i) already enrolled in the study, ii) are interested or can be
40 approached about the study, or iii) have declined study enrolment and should not be reapproached.
41
42

43 As outlined above, until SuperMIX Cohort recruitment targets are met, all eligible clients will first be
44 invited to participate in the SuperMIX Cohort but where this is declined, clients will be invited to
45 enrol in the SIRX-R Cohort. Once SuperMIX Cohort recruitment targets are met, all following
46 recruitment will be for the SIRX-R Cohort.
47
48

49 All questionnaires will be administered using computers and tablets programmed using REDCap
50 electronic data capture software hosted at the Burnet Institute.⁵⁵
51
52

53 *Data sources*
54

55
56 *Self-report annual questionnaire data*
57

58 The SuperMIX Cohort questionnaire collects information on sociodemographics, substance use and
59 treatment, drug markets and purchasing, MSIR facility use and non-use, injecting-related harms,
60

health and well-being including mental health (the PHQ-SADS – anxiety and depression⁵⁶) and social functioning (the SF8⁵⁷ or EQ5-D and the Personal Wellbeing Index⁵⁸), health service use, stigma, and violence and criminal justice (Table 1). The questionnaire for the SIRX-R Cohort will be a truncated version of the SuperMIX Cohort baseline questionnaire (questionnaires are available on request from the Principal Investigator).

Table 1 SIRX-R & SuperMIX data domains

| Domain | Content |
|---|---|
| Sociodemographics | Age, sex, gender identity, country of birth, ethnicity, indigenous identity, education and employment status, housing. |
| Substance use and treatment exposure | Drug type(s) used and injected, frequency of use and injecting, injecting initiation, current injecting behaviours, alcohol use, tobacco and e-cigarette use, substance use treatment. |
| Drug markets and purchasing | Cost and location of recent heroin and methamphetamine purchases. |
| MSIR service use | Frequency of service use, reasons for use, non-use, discontinuation of use, onsite harm reduction service access, provision of service referrals and uptake. |
| Injecting-related harms | Overdose history, recent opioid overdose, recent methamphetamine overdose, injecting-related injuries and infections, blood borne viruses (including HIV/HCV treatment). |
| Health and well-being | General health conditions, women's sexual and reproductive health, General Anxiety and Depression 7-item scale (GAD-7), reasons for health service access, EQ-5D, Patient Health Questionnaire (PHQ), |
| Health service use | Use of primary and specialist health services and reasons for use. |
| Stigma | Experience of stigma or discrimination related to drug use. |
| Violence and criminal justice | Violent victimisation, police contact, imprisonment history. |

Record linkage data

Record linkage to routinely collected administrative data sources to measure health service utilisation will occur over the study period, with participants also requested to consent for longer-term record linkage. Using the SuperMIX Cohort record linkage framework,¹⁴ participants' will be asked to consent for linkage to databases capturing MSIR facility use, specialist and primary healthcare consultations, prescription medication dispensations, Victorian emergency and tertiary health service presentations, specialist drug treatment service contacts, criminal justice contacts, and death records. All databases are outlined in Table 2. Linkage will be undertaken by accredited linkage authorities following approval from all data custodians. Linked data will be stored in a secure data storage and analysis environment such as the Sax Institute's SURE system.^{59 14}

Table 2 Administrative databases for linkage

| Source Database | Description | Key variables |
|-----------------|-------------|---------------|
|-----------------|-------------|---------------|

| | | |
|---|--|---|
| MSIR Client Database* | Records of all client visits to the MSIR. | Visit date and time to determine number of visits per person. |
| Medicare Benefits Schedule (MBS) | Records of all primary healthcare services provided through government subsidised program. | Service date, Medicare item number and description. |
| Pharmaceutical Benefits Scheme (PBS) | Records of all dispensations of medications available through the government-subsided program. | Date of dispensation, medication type. |
| Victorian Admitted Episodes Database (VAED) | Records of all admissions and separations from Victorian hospitals. | Admission date and time, separation date and time, primary and secondary diagnoses, treatment procedures. |
| Victorian Emergency Minimum Dataset (VEMD) | Records of all presentations to Victorian hospital emergency departments. | Arrival date and time, separation date and time, mode of arrival, triage category, primary and secondary diagnoses, departure status. |
| Victorian Ambulance Clinical Information System (VACIS) | Records of all patient care events attended to by Ambulance Victoria. | Arrive date and time, location, patient clinical indicators, case information, primary incident assessment, transport. |
| Victorian Public Mental Health Database | Records of all episodes of care delivered by Victorian public mental health services including inpatient and community care. | Admission/contact date and time, separation date and time, crisis assessment, primary and secondary diagnoses, patient legal status. |
| Victorian Drug and Alcohol Collection (VADC) | Specialist drug and alcohol treatment service contacts in Victoria. | Treatment start and end date, service type, client substance use. |
| Law Enforcement Assistance Program (LEAP) | Records of all contacts with Victoria Police. | Contact date and time, details of offence of reason for contact, outcome of police contact. |
| Corrections Victoria (CV) | All episodes of imprisonment in Victoria. | Prison reception and discharge dates. |
| National Death Index (NDI) | Mortality information for all deaths occurring in Australia. | Date and cause of death. |
| Note * These data will be used in exposure derivation. | | |

Measures

Outcomes

Derived from the legislated aims of the MSIR, the primary outcomes will be observed reductions in all-cause and drug-related mortality and ambulance attendances for non-fatal overdose. Secondary outcomes include reductions in drug-related hospitalisations such as injecting-related injuries and infections, and increased uptake of OAT (where indicated) and other non-acute health services.

Exposures

The primary exposure for the SIRX Study is time-varying frequency of SIF use. Participants will be categorised as frequent (\geq weekly) or infrequent ($<$ weekly) users of the MSIR based on facility utilisation rates determined from MSIR client database records, which will vary across time as people change their frequency of SIF use. For the SuperMIX Cohort, participants will also be able to be categorised as frequent ($\geq 50\%$ of their injections) or infrequent ($< 50\%$ of their injections) users of the MSIR facility on the basis of self-report questions currently implemented in the SuperMIX survey.⁶⁰ Non-MSIR controls will be SuperMIX Cohort participants who indicate they have not used the MSIR, which may change over time.

Statistical analyses

SIRX-R cohort

Mortality. We will undertake appropriate survival modelling (e.g. Cox regression or parametric [accelerated failure time or proportional hazards]) to estimate the association between MSIR use and mortality, taking account of factors that might confound the association. In these models MSIR use will be estimated as a time-varying exposure using person-period/episode split data. Prior use of the MSIR (before SIRX Study enrolment) will be considered when accounting for possible left truncation bias in these analyses. To provide more robust causal inference using data from the SIRX-R Cohort, we will also explore application of a case-time-control method to provide fixed effects estimation implicitly controlling for all time-invariant measured and unmeasured confounders (e.g., prior overdose history, time since first injection, prior level of health care usage and treatment utilisation, general health at baseline, sex).⁶¹ This statistical model will be implemented via an exposure/outcome reversed conditional logistic regression analysis on discrete-time participant-period data representing the follow-up durations for each participant (e.g., days), ending in either death or censorship.

Ambulance-attended non-fatal overdose. We will undertake generalised linear mixed modelling (GLMM, e.g. Poisson (with bootstrapped standard errors) or negative binomial) on person-period data (i.e., repeated ambulance-attended overdoses per participant measured periodically) to estimate the association between MSIR use and ambulance-attended non-fatal overdose. As stated for mortality analyses, we will implicitly control for all measured and unmeasured time-invariant confounders, a fixed-effects generalised linear modelling (Poisson or negative binomial) approach will be also explored using person-period data.

SuperMIX Cohort

Mortality and ambulance-attended non-fatal overdose. To estimate the total causal effect (also referred to as the average causal treatment effect) of participant MSIR use on mortality and ambulance-attended non-fatal overdose suitable causal inference statistical modelling (e.g., Marginal Structural Modelling⁶² [MSM] or sequential conditional mean modelling⁶³ [SCMM]) will be undertaken on annual participant person-period data. In both these modelling methods, under certain assumptions and conditions, and through different adjustment approaches (inverse

probability weighting [IPW] for MSM and prior confounder/measure conditioning for SCMM possibly combined with IPWs to provide doubly robust estimation), time-independent and time-dependent confounding can be adjusted for to estimate total causal effects, without risk of introducing over-control bias (time-dependent confounding). Generalised linear modelling and generalised estimating equations will be used to implement MSMs and SCMMs respectively, with the appropriate distributional assumptions and link functions applied given specific outcome measurement (event-history modelling for morbidity and non-normal repeated measures estimating equations for ambulance-attended non-fatal overdose). Data generating processes will be postulated using directed acyclic graphs, and these will inform the necessary structure of the statistical models to enable identification and estimation of total causal effects. Data generating processes will also help inform the application of regression modelling.

Statistical Power

Table 3 below details the approximate minimum detectable differences for mortality and non-fatal overdose analyses based on the expected distribution of participants in each cohort. Monte Carlo simulation modelling (using Generalised linear mixed modelling [GLMM]) was used to estimate minimum detectable differences for non-fatal overdose and an exponential proportional hazards parametric survival model used for mortality. Baseline hazards (mortality: 1.1 per 100PY) and incidence rates (non-fatal overdose: 8.8 per 100PY) applying to each comparison were taken from current SuperMIX cohort data,⁶⁴ as were the means and variance components used for the longitudinal GLMM simulations. All effect size estimations assumed 80% power and 5% significance. For Monte Carlo simulated analyses (n=300 replications), simulations were based on three annual outcome measurements and expected cohort attrition (SuperMIX analyses) of 30% in year 1 and 25% thereafter.

| Table 3 Minimum detectable effect sizes for outcomes | | | |
|---|--|----------------|--------------------|
| SIRX Study | Comparison | Mortality (HR) | non-fatal OD (IRR) |
| SIRX-R Cohort | Frequent (weekly) vs. infrequent. (< weekly) use | 0.42 | 0.69 |
| SuperMIX Cohort | Frequent (≥ 50% all injections) vs. no use | 0.3 | 0.58 |
| SuperMIX Cohort | Infrequent (< 50% injections) vs. no use | 0.37 | 0.64 |
| Note: SIRX-R = Supervised Injecting Room Registration Cohort, SuperMIX = Melbourne Injecting Drug User Cohort, OD = overdose, HR = Hazard Ratio, IRR = Incidence Rate Ratio | | | |

Economic evaluation

Cost data will be available to enable economic modelling. Health economic outcomes will be considered from a government perspective, compared across the categories of MSIR exposure after weighting for cohort size. The main outcomes will be (1) the difference in total annual costs; (2) the cost per life saved; and (3) the cost per quality-adjusted life year (QALY) gained. Total costs will include costs associated with MSIR use (calculated from financial documentation and budgets over time), costs of ambulance callouts for overdoses (available on Ambulance Victoria website),

healthcare costs (matching linked healthcare usage data with corresponding MBS/PBS codes, in particular costs associated with managing blood borne virus or injecting related injuries), and OAT treatment costs. QALY gains will be estimated based on additional OAT uptake, treatment of comorbidities (e.g. hepatitis C) and deaths averted that are attributable to the MSIR. Cost per QALY gained outcomes will enable benchmarking of the MSIR against other health interventions.

Patient and public involvement

The SIRX Study was designed in partnership with key stakeholders including Harm Reduction Victoria, the peak body for people who use and inject drugs in Victoria; North Richmond Community Health, the primary health service operating the Melbourne MSIR; cohealth, a not-for-profit community health organisation providing health services including services and support for alcohol and other drugs; and the Victorian State Government. These stakeholders, along with study investigators, contribute to ongoing oversight of the study via their involvement in the SIRX Study Research Advisory group.

Discussion

The SIRX Study has been designed to provide new evidence on the effectiveness of SIFs in reducing overdose deaths and drug-related harms within the Australian context. Previous research has highlighted the benefits of the Melbourne MSIR, but is limited by short evaluation timeframes, reliance on ecological data, or the absence of temporality to control for confounding and determine causation.^{35, 47, 48} Drawing on the cohort methodology used to evaluate Insite SIF in Canada,⁵² our study aims to generate quantitative evidence of the impact of SIFs, overcoming limitations described above, that also can be synthesised with other future studies.

Limitations

The SIRX study, while valuable in measuring the effectiveness of Melbourne's MSIRs in reducing drug-related harm, is subject to several limitations. Self-report data may be subject to response biases, including recall and socially desirable responding. The SuperMIX Cohort component may be subject to lost-to-follow-up; previous work demonstrated stable attrition in the SuperMIX Cohort with higher attrition among individuals with greater risk profiles.⁶⁵ However, using linked data for primary outcomes mitigates the risk of such biases. Despite the large projected sample size, the expected effect estimates for mortality remain relatively imprecise in contrast to the effects on non-fatal overdose. As with all observational studies, confounding may impact the observed associations, but causal inference methods are being applied to minimise this. Finally, selection bias may mean the study is not representative of all Melbourne MSIR clients and findings may not be generalisable to other SIFs. However, the use of comprehensive time-dependent data collected across a range of individual and health-related factors, combined with the use of causal inference methods, means the SIRX Study will generate strong evidence on the SIF effectiveness.

Conclusion

The SIRX Study uses a cohort and quasi-experimental design to measure the effectiveness of SIFs in reducing drug-related harms. Linking MSIR clients with their SIF client database and administrative

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

health records provides robust measurements of the impact of the MSIR on drug-related harms and health service use over time.

For peer review only

Enseignement Supérieur (ABES) .
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Ethics and dissemination

Ethics approval

SuperMIX Study (599/21) and SIRX-R Study (71/23) ethics approvals were obtained from Alfred Hospital Research Ethics Committee. Participants will be assessed for capacity to provide informed consent following a detailed explanation of the study. Participants are informed of their right to withdraw from the study at any time and that withdrawing does not impact their access to services.

Results dissemination

Aggregated research results will be disseminated via presentations at national and international scientific conferences and publications in peer-reviewed journals. Local-level reports and outputs will be distributed to key study stakeholders and policymakers. Summary findings for participants will be displayed in relevant services and the study van, via accessible outputs (e.g., short infographics summaries).

Acknowledgements

We acknowledge the contribution of SuperMIX and SIRX-R participants, the Burnet Institute fieldwork team, staff at the Melbourne Supervised Injecting Room, and supporting community services and organizations.

Funding

The SIRX study is funded by an NHMRC Partnership Projects grant (#2019034). Baseline data collection for SuperMIX was funded by the Colonial Foundation Trust and the NHMRC (#545891, #1126090), with ongoing data collection funded by an NHMRC Clinical Trials and Cohort Studies grant (#2023690). The authors gratefully acknowledge the support of the Victorian Operational Infrastructure Fund. The funders had no input into the work.

Author contributions

The study concept and design was conceived by PD, PH, AR, NS, TK, DO, PA, AT, NC, LM, MS, and MH. PD, AS, PH, DVH, ZL and MH assisted in refining the study questionnaires and study protocols. AS leads the study coordination and implementation. DVH and ZL are leading data collection. Analyses will be conducted by PA, NS and JS. SC and JN provide key stakeholder input and guidance. AS, MH and PD prepared the first draft of the manuscript. All authors critically revised the manuscript and approved the submitted version.

Data statement

Data for the SIRX Study are securely housed on the Burnet Institute server and an accredited secure research environment as per the requirements of relevant data custodians. Only researchers with ethics approval will have access to data. Requests for access to datasets generated for the SIRX study should be made to the corresponding author or Principal Investigator (PD).

References

1. Larney S, Peacock A, Leung J, Colledge S, Hickman M, Vickerman P, et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. *Lancet Glob Health*. 2017;5(12):e1208-e20.

2. Mathers BM, Degenhardt L, Bucello C, Lemon J, Wiessing L, Hickman M. Mortality among people who inject drugs: a systematic review and meta-analysis. *Bull World Health Organ*. 2013;91(2):102-23.

3. Degenhardt L, Webb P, Colledge-Frisby S, Ireland J, Wheeler A, Ottaviano S, et al. Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic review. *Lancet Glob Health*. 2023;11(5):e659-e72.

4. Tait R, Allsop S, eds. *Quantifying the Social Costs of Pharmaceutical Opioid Misuse & Illicit Opioid Use to Australia in 2015/16*. Perth, Western Australia: NDRI; 2020.

5. Whetton S, Shanahan M, Cartwright K, Duraisingam V, Ferrante A, Gray D, et al. *The Social Costs of Methamphetamine in Australia 2013/14*. Perth, WA; 2016.

6. Kirwan A, Quinn B, Winter R, Kinner SA, Dietze P, Stoovn M. Correlates of property crime in a cohort of recently released prisoners with a history of injecting drug use. *Harm Reduction Journal*. 2015;12(1).

7. Nambiar D, Spelman T, Stoové M, Dietze P. Are People Who Inject Drugs Frequent Users of Emergency Department Services? A Cohort Study (2008–2013). *Substance use & misuse*. 2018;53(3):457-65.

8. Nambiar D, Stoové M, Hickman M, Dietze P. A prospective cohort study of hospital separations among people who inject drugs in Australia: 2008–2013. *BMJ Open*. 2017;7(8).

9. Darke S, Torok M. Childhood physical abuse, non-suicidal self-harm and attempted suicide amongst regular injecting drug users. *Drug Alcohol Depend*. 2013;133(2):420-6.

10. Darke S, Torok M. The association of childhood physical abuse with the onset and extent of drug use among regular injecting drug users. *Addiction*. 2014;109(4):610-6.

11. Richardson L, Wood E, Kerr T. The impact of social, structural and physical environmental factors on transitions into employment among people who inject drugs. *Soc Sci Med*. 2013;76(1):126-33.

12. Topp L, Iversen J, Baldry E, Maher L, Collaboration of Australian N. Housing instability among people who inject drugs: results from the Australian needle and syringe program survey. *Journal of urban health : bulletin of the New York Academy of Medicine*. 2013;90(4):699-716.

13. Arum C, Fraser H, Artenie AA, Bivegete S, Trickey A, Alary M, et al. Homelessness, unstable housing, and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. *The Lancet Public Health*. 2021.

14. Van Den Boom W, Quiroga MDM, O'Keefe D, Kumar D, Hill PL, Scott N, et al. Cohort Profile: The Melbourne Injecting Drug User Cohort Study (SuperMIX). *International journal of epidemiology*. 2021.

15. Winter RJ, Stoove M, Agius PA, Hellard ME, Kinner SA. Injecting drug use is an independent risk factor for reincarceration after release from prison: A prospective cohort study. *Drug Alcohol Rev*. 2019;38(3):254-63.

16. Dolan K, Wirtz AL, Moazen B, Ndeffo-Mbah M, Galvani A, Kinner SA, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. *The Lancet*. 2016;388(10049):1089-102.

17. Aldridge RW, Story A, Hwang SW, Nordentoft M, Luchenski SA, Hartwell G, et al. Morbidity and mortality in homeless individuals, prisoners, sex workers, and individuals with substance use disorders in high-income countries: a systematic review and meta-analysis. *The Lancet*. 2018;391(10117):241-50.

18. Tsai AC, Kiang MV, Barnett ML, Beletsky L, Keyes KM, McGinty EE, et al. Stigma as a fundamental hindrance to the United States opioid overdose crisis response. *PLOS Medicine*. 2019;16(11):e1002969.
19. Nambiar D, Stooze M, Dietze P. Frequent emergency department presentations among people who inject drugs: A record linkage study.(Report). *International Journal of Drug Policy*. 2017;44:115.
20. Fernandes RM, Cary M, Duarte G, Jesus G, Alarcão J, Torre C, et al. Effectiveness of needle and syringe Programmes in people who inject drugs - An overview of systematic reviews. *BMC Public Health*. 2017;17(1):309.
21. Curtis M, Wilkinson AL, Dietze P, Stewart AC, Kinner SA, Winter RJ, et al. Is use of opioid agonist treatment associated with broader primary healthcare use among men with recent injecting drug use histories following release from prison? A prospective cohort study. *Harm Reduction Journal*. 2023;20(1):42.
22. Colledge-Frisby S, Ottaviano S, Webb P, Grebely J, Wheeler A, Cunningham EB, et al. Global coverage of interventions to prevent and manage drug-related harms among people who inject drugs: a systematic review. *Lancet Glob Health*. 2023;11(5):e673-e83.
23. European Monitoring Centre for Drugs and Drug Addiction. Perspectives on drugs - Drug consumption rooms: an overview of provision and evidence. EMCDDA; 2018.
24. Kerr T, Wood E, Montaner J, Tyndall M. Findings from the evaluation of Vancouver's pilot medically supervised safer injection facility—Insite (UHRI Report). Vancouver, BC: BC Centre for Excellence in HIV/AIDS: Addiction and Urban Health Research Initiative; 2009.
25. Milloy MJS, Kerr T, Tyndall M, Montaner J, Wood E. Estimated Drug Overdose Deaths Averted by North America's First Medically-Supervised Safer Injection Facility. *PLOS ONE*. 2008;3(10):e3351.
26. Jozaghi E, Reid AA. The Potential Role for Supervised Injection Facilities in Canada's Largest City, Toronto. *International Criminal Justice Review*. 2015;25(3):233-46.
27. Small W, Wood E, Lloyd-Smith E, Tyndall M, Kerr T. Accessing care for injection-related infections through a medically supervised injecting facility: A qualitative study. *Drug and alcohol dependence*. 2008;98(1):159-62.
28. Kennedy MC, Hayashi K, Milloy MJ, Wood E, Kerr T. Supervised injection facility use and all-cause mortality among people who inject drugs in Vancouver, Canada: A cohort study. *PLoS Med*. 2019;16(11):e1002964.
29. Salmon AM, van Beek I, Amin J, Kaldor J, Maher L. The impact of a supervised injecting facility on ambulance call-outs in Sydney, Australia. *Addiction*. 2010;105(4):676-83.
30. Lambdin BH, Davidson PJ, Browne EN, Suen LW, Wenger LD, Kral AH. Reduced Emergency Department Visits and Hospitalisation with Use of an Unsanctioned Safe Consumption Site for Injection Drug Use in the United States. *Journal of General Internal Medicine*. 2022;37(15):3853-60.
31. Kennedy MC, Hayashi K, Milloy MJ, Boyd J, Wood E, Kerr T. Supervised injection facility use and exposure to violence among a cohort of people who inject drugs: A gender-based analysis. *Int J Drug Policy*. 2020;78:102692.
32. Fairbairn N, Small W, Shannon K, Wood E, Kerr T. Seeking refuge from violence in street-based drug scenes: Women's experiences in North America's first supervised injection facility. *Social Science & Medicine*. 2008;67(5):817-23.
33. Kerr T, Tyndall M, Li K, Montaner J, Wood E. Safer injection facility use and syringe sharing in injection drug users. *Lancet*. 2005;366(9482):316-8.
34. Pinkerton SD. How many HIV infections are prevented by Vancouver Canada's supervised injection facility? *Int J Drug Policy*. 2011;22(3):179-83.
35. Van Den Boom W, del Mar Quiroga M, Fetene DM, Agius PA, Higgs PG, Maher L, et al. The Melbourne Safe Injecting Room Attracted People Most in Need of Its Service. *Am J Prev Med*. 2021;61(2):217-24.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

36. Reddon H, Wood E, Tyndall M, Lai C, Hogg R, Montaner J, et al. Use of North America's first medically supervised safer injecting facility among HIV-positive injection drug users. *AIDS education and prevention : official publication of the International Society for AIDS Education*. 2011;23(5):412-22.

37. Wood E, Tyndall MW, Li K, Lloyd-Smith E, Small W, Montaner JSG, et al. Do Supervised Injecting Facilities Attract Higher-Risk Injection Drug Users? *American Journal of Preventive Medicine*. 2005;29(2):126-30.

38. Wood E, Kerr T, Small W, Li K, Marsh DC, Montaner JSG, et al. Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users. *CMAJ*. 2004;171(7):731-4.

39. Salmon AM, Thein HH, Kimber J, Kaldor JM, Maher L. Five years on: what are the community perceptions of drug-related public amenity following the establishment of the Sydney Medically Supervised Injecting Centre? *Int J Drug Policy*. 2007;18(1):46-53.

40. Maher L, Salmon A. Supervised injecting facilities: how much evidence is enough? *Drug Alcohol Rev*. 2007;26(4):351-3.

41. Christie T, Wood E, Schechter MT, O'Shaughnessy MV. A comparison of the new Federal Guidelines regulating supervised injection site research in Canada and the Tri-Council Policy Statement on Ethical Conduct for Research Involving Human Subjects. *International Journal of Drug Policy*. 2004;15(1):66-73.

42. Levensgood TW, Yoon GH, Davoust MJ, Ogden SN, Marshall BDL, Cahill SR, et al. Supervised Injection Facilities as Harm Reduction: A Systematic Review. *Am J Prev Med*. 2021;61(5):738-49.

43. Kerr T, Mitra S, Kennedy MC, McNeil R. Supervised injection facilities in Canada: past, present, and future. *Harm Reduction Journal*. 2017;14(1):28.

44. Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. *The Lancet Global Health*. 2017;5(12):e1192-e207.

45. Iversen J, Wand H, Topp L, Kaldor J, Maher L. Extremely low and sustained HIV incidence among people who inject drugs in a setting of harm reduction. *AIDS*. 2014;28(2):275-8.

46. Dwyer R, Power R, Denham G, Dietze P. Public injecting and public amenity in an inner-city suburb of Melbourne, Australia. *Journal of Substance Use*. 2014:1-8.

47. MSIR Review Panel. Review of the MSIR. Melbourne. Victoria: State Government of Victoria; 2020.

48. MSIR Review Panel. Review of the Medically Supervised Injecting Room. Melbourne; 2023.

49. ABC News. Safe injecting room trial extended in North Richmond, new facility slated for near Queen Victoria Market in Melbourne CBD. ABC News. 2020.

50. Willingham R, Rollason B. Victorian government scraps plans for a second supervised injecting room in Melbourne. ABC News. 2024.

51. Carey A, Dow A. Victorian Liberals to shut down injecting room in a week if elected. *The Age*. 2018.

52. Wood E, Kerr T, Lloyd-Smith E, Buchner C, Marsh DC, Montaner JSG, et al. Methodology for evaluating Insite: Canada's first medically supervised safer injection facility for injection drug users. *Harm Reduction Journal*. 2004;1(1):9.

53. MacIsaac M, Whitton B, Anderson J, al. e. Rapid point-of-care hepatitis C testing in a medically supervised injecting room. *EASL Congress*; 23-26 June 20212021.

54. MacIsaac MB, Whitton B, Anderson J, Cogger S, Vella-Horne D, Penn M, et al. Point-of-care HCV RNA testing improves hepatitis C testing rates and allows rapid treatment initiation among people who inject drugs attending a medically supervised injecting facility. *Int J Drug Policy*. 2024;125:104317.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

55. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: Building an international community of software platform partners. *J Biomed Inform.* 2019;95:103208.
56. Kroenke KMD, Spitzer RLMD, Williams JBWDSW, Löwe BMDPD. The Patient Health Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: a systematic review. *General hospital psychiatry.* 2010;32(4):345-59.
57. Ware JE, Kosinski M, Dewey JE, Gandek B. How to Score and Interpret Single-Item Health Status Measures: A Manual for Users of the SF-8 Health Survey (With a Supplement on the SF-6 Health Survey). Lincoln, Rhode Island: QualityMetric Incorporated; 2001.
58. International Wellbeing Group. PWI. Melbourne: Australian Centre on Quality of Life; 2006.
59. Sax Institute. Secure Unified Research Environment (SURE). Sax Institute; 2024.
60. Artenie A, Stone J, Fraser H, Stewart D, Arum C, Lim AG, et al. Incidence of HIV and hepatitis C virus among people who inject drugs, and associations with age and sex or gender: a global systematic review and meta-analysis. *The Lancet Gastroenterology & Hepatology.* 2023;8(6):533-52.
61. Suissa S. The Case-Time-Control Design. *Epidemiology (Cambridge, Mass).* 1995;6(3):248-53.
62. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. *Epidemiology.* 2000;11(5):550-60.
63. Keogh RH, Daniel RM, VanderWeele TJ, Vansteelandt S. Analysis of Longitudinal Studies With Repeated Outcome Measures: Adjusting for Time-Dependent Confounding Using Conventional Methods. *Am J Epidemiol.* 2018;187(5):1085-92.
64. Hill PL, Stoové M, Agius PA, Maher L, Hickman M, Crawford S, et al. Mortality in the SuperMIX cohort of people who inject drugs in Melbourne, Australia: a prospective observational study. *Addiction.* 2022;117(12):3091-8.
65. Abdelsalam S, Agius PA, Sacks-Davis R, Roxburgh A, Livingston M, Maher L, et al. Characteristics of attrition within the SuperMIX cohort of people who inject drugs: A multiple event discrete-time survival analysis. preprint. 2024.




Figure 1 Study design of the SIRX Study

Figure 1 Study design of the SIRX Study

1002x534mm (38 x 38 DPI)

BMJ Open

Supervised injecting room cohort study (SIRX): study protocol

| | |
|---------------------------------|--|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2024-091337.R1 |
| Article Type: | Protocol |
| Date Submitted by the Author: | 20-Dec-2024 |
| Complete List of Authors: | Stewart, Ashleigh; Burnet Institute, Behaviours and Health Risks; Monash University, School of Public Health and Preventive Medicine Hickman, Matthew; University of Bristol, Population Health Sciences; National Drug and Alcohol Research Centre; Burnet Institute Agius, Paul A.; Burnet Institute; Deakin University Faculty of Health Scott, Nick; Burnet Institute; Monash University, School of Public Health and Preventive Medicine Stone, Jack ; University of Bristol, Population Health Sciences Roxburgh, Amanda; Burnet Institute; Monash University, School of Public Health and Preventive Medicine O'Keefe, Daniel; Burnet Institute; Monash University, School of Public Health and Preventive Medicine Higgs, Peter; Burnet Institute, Behaviours and Health Risks; La Trobe University, Public Health Kerr, Thomas; The University of British Columbia Department of Medicine, Division of Social Medicine; British Columbia Centre on Substance Use Stoové, Mark; Burnet Institute; Monash University, School of Public Health and Preventive Medicine Thompson, Alexander; St Vincent's Hospital Melbourne, Department of Gastroenterology; The University of Melbourne, Department of Medicine Crawford, S; Harm Reduction Victoria Norman, Josephine; Department of Health Victoria, Centre for Evaluation and Research Evidence Vella-Horne, Dylan; Burnet Institute, Behaviours and Health Risks Lloyd, Zachary ; Burnet Institute, Behaviours and Health Risks Clark, Nico; Burnet Institute, Behaviours and Health Risks Maher, Lisa; The Kirby Institute; Burnet Institute Dietze, Paul; Burnet Institute; National Drug Research Institute |
| Primary Subject Heading: | Addiction |
| Secondary Subject Heading: | Public health |
| Keywords: | Drug Utilization, Health Services, Substance misuse < PSYCHIATRY |
| | |



Title page

Supervised injecting room cohort study (SIRX): study protocol

Authors: Stewart AC^{1,2}, Hickman M^{3,4}, Agius PA^{1,5}, Scott N^{1,2}, Stone J³, Roxburgh A^{1,2}, O’Keefe D^{1,2}, Higgs P^{1,7}, Kerr T^{8,9}, Stoové M^{1,2}, Thompson A^{10,11}, Crawford S¹², Norman J¹³, Vella-Horne D¹, Lloyd Z¹, Clark N¹, Maher L^{1,14}, Dietze PM^{1,2,5}

Corresponding Author: Ashleigh Stewart – Ashleigh.stewart@burnet.edu.au

Author emails:

1. Matthew.Hickman@bristol.ac.uk
2. p.agius@deakin.edu.au
3. nick.scott@burnet.edu.au
4. j.stone@bristol.ac.uk
5. Amanda.Roxburgh@burnet.edu.au
6. daniel.okeefe@burnet.edu.au
7. peter.higgs@burnet.edu.au
8. thomas.kerr@bccsu.ubc.ca
9. mark.stoove@burnet.edu.au
10. alexander.thompson@svha.org.au
11. sionec@hrvic.org.au
12. Josephine.Norman@health.vic.gov.au
13. dylan.vella-horne@burnet.edu.au
14. zachary.lloyd@burnet.edu.au
15. nico.clark@gmail.com
16. Lmaher@kirby.unsw.edu.au
17. Paul.dietze@burnet.edu.au

Affiliations:

1. Disease Elimination, Burnet Institute, Melbourne, Australia
2. School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
3. Population Health Sciences, Bristol Medical School, University of Bristol, UK
4. National Drug and Alcohol Research Centre, UNSW, Sydney, Australia
5. Faculty of Health, Deakin University, Melbourne, Australia
6. National Drug Research Institute, Curtin University, Melbourne, Australia
7. School of Public Health, La Trobe University, Melbourne, Australia
8. Division of Social Medicine, Department of Medicine, University of British Columbia
9. Director of Research/Senior Scientist, British Columbia Centre on Substance Use
10. Department of Gastroenterology, St Vincent’s Hospital Melbourne, Melbourne, VIC, Australia
11. Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia
12. Harm Reduction Victoria, Melbourne, Victoria, Australia

- 13. Centre for Evaluation and Research Evidence, Department of Health, Victoria, Australia
- 14. Kirby Institute, Faculty of Medicine, UNSW Sydney

Word count: 5081

Key words: Injecting drug use, people who inject drugs, supervised injecting facility, drug consumption room, safe injection, cohort study, administrative data linkage

Competing interests:

PH and MS has received investigator-driven research funding from Gilead Sciences and Abbvie for work on hepatitis C, unrelated to this manuscript. AT Advisory board member – Abbvie, Gilead Sciences, Roche Diagnostics, BMS, Assembly Biosciences, Immunocore; Speaker – Abbvie, Gilead Sciences, Roche Diagnostics, Roche, BMS; Research/grant support – Gilead Sciences, Abbvie, Roche Diagnostics. SC has received funding from Camurus and HRVic has received funding from Indivior. JN was involved in the two reviews of the MSIR as a salaried staff member of the Department of Health. All other authors have no completing interest to declare.

PH and MS has received investigator-driven research funding from Gilead Sciences and Abbvie for work on hepatitis C, unrelated to this manuscript. AT Advisory board member – Abbvie, Gilead Sciences, Roche Diagnostics, BMS, Assembly Biosciences, Immunocore; Speaker – Abbvie, Gilead Sciences, Roche Diagnostics, Roche, BMS; Research/grant support – Gilead Sciences, Abbvie, Roche Diagnostics. SC has received funding from Camurus and HRVic has received funding from Indivior. JS was involved in the two reviews of the MSIR as a salaried staff member of the Department of Health.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES).

Abstract

Background

Supervised injecting facilities (SIFs) are designed to reduce the harms associated with injecting drug use and improve access to health and support services for people who need them. The Supervised Injecting Room Cohort Study (SIRX) aims to provide evidence of the effects, including cost-effectiveness, of a SIF embedded within a community health service, the Melbourne Medically Supervised Injecting Room (MSIR), which has a range of integrated harm reduction, health and social support services on-site.

Methods and analysis

The SIRX study design involves two prospective cohort studies that collect behavioural data and retrospectively and prospectively linked administrative data for primary and tertiary health services, criminal justice records, and mortality. The two cohorts are: 1) participants drawn from the existing Melbourne Injecting Drug User Cohort Study (SuperMIX; established in 2008–ongoing) through which participants consent to annual behavioural surveys (including serological testing for HIV and hepatitis B and C viruses) and linkage to administrative data; and 2) the SIRX-Registration Cohort (SIRX-R; established in 2024) comprising registered MSIR clients who consent to a baseline behavioural survey and administrative data linkage including the frequency of SIF use, and the uptake of on-site services. Primary outcomes are aligned to the legislated aims of the Melbourne MSIR, including ambulance attended non-fatal overdoses and all-cause and drug-related mortality. Using causal inference methods, analyses will estimate the effect of MSIR exposure (frequent use/infrequent use/no use) on these primary outcomes. The SIRX study also has a secondary focus on the effect of MSIR exposure on health service use and related outcomes.

Ethics and dissemination

SuperMIX Study (599/21) and SIRX-R Study (71/23) ethics approvals were obtained from Alfred Hospital Research Ethics Committee. Participants will be assessed for capacity to provide informed consent following a detailed explanation of the study. Participants are informed of their right to withdraw from the study at any time and that withdrawing does not impact their access to services. Aggregated research results will be disseminated via presentations at national and international scientific conferences and publications in peer-reviewed journals. Local-level reports and outputs will be distributed to key study stakeholders and policymakers. Summary findings via accessible outputs (e.g., short infographic summaries) for participants will be displayed in relevant services including the Melbourne MSIR and the study van, and distributed via Harm Reduction Victoria.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- The Supervised Injecting Room Cohort Study (SIRX) uses a cohort and quasi-experimental design to measure varying levels of exposure to the Melbourne Medically Supervised Injecting Room (MSIR) and its on-site services and the effect of these exposure levels across a range of outcomes.
- Comprehensive longitudinal behavioural data and linkage to MSIR visits and routinely collected administrative health and social databases.
- The SuperMIX Cohort may be subject to attrition bias through lost-to-follow-up, however, data linkage for primary outcomes minuses this risk.
- Consistent with all observational studies, confounding may impact the observed associations, but casual inference methods are being applied to minimise this.

Enseignement Supérieur (ABES) .
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Background

Regular injecting drug use is associated with a wide range of adverse health outcomes including drug overdose deaths, which have steadily increased in the last two decades in Australia and globally.^{1, 2} In particular, opioid-related deaths in Australia have doubled since 2001.³ Injecting-related harms also include blood-borne viral infections (e.g., HIV, viral hepatitis) and injection-related injuries and infections (e.g., skin, soft tissue injuries and endocarditis),^{1, 4} all of which are key drivers of morbidity, mortality, as well as drug-related economic costs to the community.^{5, 6} Injecting drug use is also connected to wider social and economic harms, including drug-related crime⁷ and avoidable healthcare costs,^{8, 9} many of which are related to current drug policy and the criminalisation of illicit drugs.¹⁰

Social marginalisation, stigma, and trauma are driven by myriad factors including adverse childhood experiences,^{11, 12} unemployment,¹³ persistent housing instability,^{14, 15} and imprisonment^{4, 16, 17} and compound the risks among people who inject drugs.^{18, 19} Stigma and discrimination, in particular, contributes to suboptimal health care, undermining access to supportive and harm reduction services, such as opioid agonist therapy (OAT).²⁰ Further, harms created by structural barriers and social exclusion can cause delays in seeking care, which may lead to frequent use of acute care services such as hospital emergency departments (ED).²¹

Harm reduction interventions, including needle and syringe programs (NSPs) and OAT, have been shown to be effective at reducing injecting-related harm²² and health service use²³ but program coverage of these interventions is variable in Australia and may be insufficient to reduce drug-related harms.²⁴ Further, NSPs and OAT do not provide an immediate response to acute harms, such as drug overdoses and the costs associated with managing them.

Supervised injecting facilities

Supervised injecting facilities* (SIFs) were first established in Europe in the mid-1980s in response to epidemics of public injecting, overdose, and increasing HIV incidence related to injection drug use,²⁵ and as of 2023, SIFs were legally operating in 17 (predominantly high income) countries.²⁴ SIFs, and drug consumption rooms more broadly, provide an environment where individuals can use pre-obtained drugs with sterile equipment under supervision. SIFs provide an emergency response in the event of drug overdose, facilitate referrals to other health and social services providers, and sometimes also provide a range of on-site services. While referrals from SIFs have been shown to result in the uptake of services²⁶, people who use SIFs have also demonstrated a preference to receive care on-site, due to the relationship with SIF staff, and negative experiences with mainstream health services.²⁷

Evidence from observational, modelling, ecological, and qualitative studies demonstrates that SIFs reduce a range of harms, including drug-related²⁷⁻²⁹ and all-cause mortality,³⁰ ambulance attendances for drug overdose,³¹ and ED presentations.^{32, 33} Evidence also suggests SIFs are associated with reductions in experiencing violence,^{34, 35} receptive needle and syringe sharing,³⁶ and

* Many labels are used to describe supervised drug consumption sites and overdose prevention centres. As this article is focused on facilities that only permit drug injecting under supervision, the term 'supervised injecting facility' is used throughout the article.

HIV incidence.³⁷ Further, SIFs have demonstrated effectiveness in attracting individuals at greatest risk of harm, such as those experiencing homelessness, mental illness, people who inject in public spaces and people who engage in high-risk drug use.³⁸⁻⁴⁰ SIFs have had a documented positive impact on public amenity by reducing public injecting and ensuring safe disposal of injecting equipment.^{41, 42} Thus, SIFs demonstrate utility in offering a range of harm reduction services and referrals to populations considered to be experiencing social and structural vulnerability.

Despite this evidence base, the evaluation of SIFs remains challenging with researchers determining randomised control trials to be difficult to implement and unethical for evaluating the effect of SIFs, particularly in the absence of clinical equipoise (uncertainty over evidential strength for an intervention) when intervening in the event of an overdose.^{43, 44} Thus, past evaluations have relied exclusively on observational data, which creates methodological challenges and when considering hierarchies of evidence. Further, the vast majority of international evidence in a recent review (16/22, studies, 72%) relates to a single SIF in Vancouver, Canada (Insite),⁴⁵ itself a unique risk environment for drug related harm characterised by epidemics of HIV infection and overdose.⁴⁶ Thus, there remains an ongoing need to evaluate the impacts of SIFs with many unanswered questions, as well as a need to evaluate SIFs operating in other international contexts, with different operational models, and varying drug markets, patterns of drug use and epidemiological environments. For example, previous SIF cost effectiveness studies are focused on reductions in HIV incidence, which is of limited relevance to jurisdictions such as Australia where HIV remains rare among people who inject drugs.^{47, 48}

The Melbourne Medically Supervised Injecting Room (MSIR)

The Melbourne Medically Supervised Injecting Room (MSIR) was established in 2018, in North Richmond, an inner-city suburb of Melbourne with an established street drug market.⁴⁹ The North Richmond MSIR is located in the grounds of the largest public housing estate in Australia, directly adjacent to the North Richmond Community Health Centre. Prior to the establishment of the Melbourne MSIR, local drug market activity in the North Richmond area was characterised by highly visible public injecting, injecting-related litter and high rates of fatal and non-fatal drug overdoses.⁴⁹⁻⁵¹ Within the first 18 months of operation, approximately 4000 clients registered to use the MSIR, with the facility averaging 300 visits per day following the opening of the purpose-built facility.⁵⁰

Based on consultations with people injecting drugs in the local area, the Melbourne MSIR was designed to meet their needs as a “one-stop shop”, incorporating an extensive range of on-site health and social services,⁵² including BBV testing and treatment,^{53, 54} OAT,⁵⁵ oral health care, housing support, wound care, mental health support, legal assistance, food, and primary care, as well as referral to other services when needed. The design of each of the health and social services was optimised to be responsive to the needs of the people who inject drugs, by offering simplified treatment pathways, incorporating increased flexibility in service delivery and utilising a trauma-informed approach. This resulted in a substantial uptake in on-site services, including 387 treatment initiations for Hepatitis C, and 1096 initiations of OAT,⁵⁶ in some ways distinguishing the MSIR from other SIFs.

In 2020, a MSIR service review assessed the facility against its legislated objectives to: i) reduce avoidable deaths caused by drug overdose; ii) advance delivery of effective health services to MSIR

clients; iii) reduce attendance and use of emergency and hospital services for drug overdose; iv) reduce discarded needles in public places and public injecting; v) improve neighbourhood amenity (this was not defined but typically relates to public injecting, public overdose, discarded injecting equipment, and perceived safety of the surrounding environment⁵⁷); and vi) reduce blood borne virus transmission.⁵⁰ Based on two reviews in 2020 and 2023, noted reductions in preventable deaths (including management of almost 6000 overdose events) and use of emergency services for overdose, and improvements in public amenity were observed.^{50, 58} Thus, the Government extended the MSIR operating license for three years and recommended the establishment of a second facility in the Melbourne Central Business District.⁵⁹ In 2024 following strong resistance from business owners and residents, driven by ongoing negative media and concerns about potential increases in crime and impacts on property values,⁶⁰⁻⁶² as well as the failure to establish a suitable location,⁶³ the commitment to establish the second facility was withdrawn.⁶⁴

Despite these MSIR reviews demonstrating reductions for each of the facility-specific legislated aims, data used to generate these estimates were limited by small sample sizes of MSIR clients, coupled with a short evaluation timeframe that reduced analytical power. The withdrawal of the commitment to establish a second facility highlights the precarious situation of SIFs and the need for robust evidence on the effects of SIFs, particularly in light of suggestions by the Victorian opposition that they would close the MSIR if elected.⁶⁵ To this effect the SIRX study is designed as a large-sample longitudinal cohort design to provide the strongest possible evidence of the effects of the MSIR including its on-site services model. This protocol paper describes our approach to evaluating the impacts of the Melbourne-based SIF, focused on the facility's legislated aims (outlined below) using comprehensive longitudinal data from two cohort studies of people who inject drugs.

The Melbourne Injecting Drug Use Cohort Study (SuperMIX)

Data from The Melbourne Injecting Drug User Cohort Study (SuperMIX) were used to inform part of the MSIR facility reviews. SuperMIX is the largest, only active, and longest running longitudinal study of people who inject drugs in Australia and one of the largest internationally (N>1500 enrolled participants).¹⁶ Established in 2008, SuperMIX involves annual interviews collecting detailed data on drug use and risk behaviours, drug purchasing, health service and drug treatment utilisation, health and well-being, and imprisonment. These detailed data are complemented by serological testing for HIV and viral hepatitis, and linkage to the National Death Index (NDI), national Medical and Pharmaceutical Benefits Schemes (MBS, PBS), state-wide emergency department presentations and hospitalisations, ambulance attendances, and drug treatment contacts.¹⁶

Following the MSIR opening, SuperMIX participants were asked about their level and frequency of exposure to the MSIR, annually. As part of the MSIR facility review, SuperMIX findings demonstrated that MSIR clients were more likely to identify as Aboriginal and/or Torres Strait Islander, report recent arrest, and report heroin as their main drug of choice.⁵⁰ SuperMIX participants previously reporting injecting in high-risk settings, such as in public, were almost twice as likely to visit the MSIR compared to participants not injecting in these settings. The MSIR review also found MSIR use was associated with lower rates of ambulance attendance and naloxone administration, but these findings were drawn from small samples or limited ecological data.⁵⁰

The current study will leverage the existing infrastructure of SuperMIX, particularly the study's established relationships with people who inject drugs and the MSIR service.

The current study

The Supervised Injecting Room Cohort Study (SIRX) involves a breadth of longitudinal data obtained linked to administrative health and social databases. With annually measured SuperMIX prospective cohort data linked via MSIR facility registration, SIRX presents the opportunity to implement a quasi-experimental study design permitting estimation of the causal effect of MSIR exposure (including both safe injecting and the use of on-site services) using causal inference methods. This study design was successfully applied in Vancouver,⁶⁶ providing the strongest evidence to date of SIF effectiveness.⁴⁵ SIRX will broaden the evidence base for SIFs to inform harm reduction responses to reduce injecting-related harms particularly in Australia given opioid-related deaths have doubled since 2001.

SIRX aims to provide further evidence of the effects, including cost-effectiveness, of SIFs by estimating the total causal effect of MSIR use on all-cause and opioid related mortality and non-fatal overdose. This study design will also allow for new evidence on additional secondary outcomes related to SIF use such as self-reported public injecting, public syringe disposal, and receptive syringe sharing, and enhanced hepatitis C treatment and health protective behaviours including vaccination (e.g., COVID-19 and hepatitis B). It will also allow for a cost-effectiveness analysis to be undertaken that combines a broader set of MSIR benefits, which have not previously been able to be quantified.

Aims

The primary aim of the SIRX study is to estimate longitudinal associations and any causal effects between MSIR use and non-fatal overdose and mortality, and linked secondary aims are to examine similar effects on additional outcomes, including tertiary health service and drug treatment uptake. The study will also evaluate the cost effectiveness of the MSIR service in relation to these aims.

Methods

Study setting & design

The SIRX Study will be undertaken across Melbourne, Australia, with a particular focus on North Richmond, an inner suburb of Melbourne where the MSIR is located. The SIRX Study utilises a cohort and quasi-experimental design in which MSIR clients and people who inject drugs with varying levels of MSIR exposure are compared across a range of behavioural and linked administrative outcome data. Two cohorts will contribute to the SIRX Study, the SuperMIX Cohort and the SIRX-Registration (SIRX-R) Cohort (Figure 1).

Participant eligibility

MSIR clients will be eligible for the SIRX Study if they attend and use the MSIR in the six months prior to study contact and consent to an interview and record linkage. Participants also provide

1
2
3 unspecified consent for their data to be used in other ethically approved studies involving project
4 investigators. Currently, MSIR clients must be aged 18+ years and have initiated injecting drugs prior
5 to MSIR registration and are neither on parole nor pregnant; SIRX Study eligibility will align with
6 these requirements, which are similar to SuperMIX eligibility.¹⁶ Clients provide minimal information
7 when registering and are given an anonymous client number, allowing for internal tracking on an
8 MSIR database. Data on the utilisation of on-site health and social services is incorporated into the
9 analysis.
10
11

12 13 *Study recruitment*

14
15
16 A total of 3,000 registered MSIR clients will be recruited into the SIRX Study. MSIR data show
17 approximately 3,600 individual clients access the MSIR every nine months, indicating the need to
18 recruit every second client to complete recruitment in the expected nine-month recruitment period.
19 Previous experience indicates rapid recruitment of a large number of participants using these
20 methods.⁶⁶ Recruitment inside the MSIR will be led by a cohort navigator who will work closely with
21 research staff and MSIR staff to facilitate participant recruitment. Research staff receive extensive
22 training in obtaining informed consent and undertaking field-based data collection and survey
23 administration,⁶⁷ and adhere to standard operating procedures developed for fieldwork undertaken
24 inside the MSIR. Recruitment commenced in September 2024 with final follow-ups to be completed
25 by December 2027.
26
27

28
29 SIRX Study enrolment and survey completion will occur post-injection either inside the MSIR or in a
30 research study van located outside the MSIR. Previous research demonstrates post-injection
31 interviews and testing is feasible at the North Richmond MSIR.^{53, 68} Researchers are trained to
32 monitor for signs of heavy intoxication and reschedule interviews in line with current research
33 standard operating protocols. Recruitment processes for SuperMIX and SIRX-R are detailed below.
34
35

36 37 *SuperMIX Cohort*

38
39
40 A total of 1200 registered MSIR clients will be recruited into the SuperMIX Cohort for annual surveys
41 and record linkage (including MSIR client records). This target recruitment sample consists of 360
42 participants already enrolled in SuperMIX and who report using the MSIR and approximately 840
43 new SuperMIX participants who are recruited directly from the MSIR. We will first consecutively
44 invite all MSIR clients to participate in SuperMIX until the target sample size is reached. Participants
45 recruited into SuperMIX will be reimbursed AUD\$40 for baseline and follow-up surveys and AUD\$10
46 for providing a blood-bio sample (total reimbursement AUD\$50).
47
48

49
50 The SuperMIX Cohort will also provide a study control group of people who inject drugs who do not
51 report using the MSIR (Figure 1).
52

53 54 *SIRX-R Cohort*

55
56 A total of 1800 participants will be recruited into the SIRX-R Cohort who will consent to record
57 linkage (including MSIR client records) and complete a once-off cross-sectional survey. To streamline
58 recruitment and reduce client burden, a SIRX Study data field will be added to the MSIR client
59
60

database to identify clients who are i) already enrolled in the study, ii) are interested or can be approached about the study, or iii) have declined study enrolment and should not be reapproached.

As outlined above, until SuperMIX Cohort recruitment targets are met, all eligible clients will first be invited to participate in the SuperMIX Cohort but where this is declined, clients will be invited to enrol in the SIRX-R Cohort. Once SuperMIX Cohort recruitment targets are met, all following recruitment will be for the SIRX-R Cohort.

All questionnaires will be administered using computers and tablets programmed using REDCap electronic data capture software hosted at the Burnet Institute.⁶⁹

Data sources

Self-report annual questionnaire data

The SuperMIX Cohort questionnaire collects information on sociodemographics, substance use and treatment, drug markets and purchasing, MSIR facility use and non-use, injecting-related harms, health and well-being including mental health (the PHQ-SADS – anxiety and depression⁷⁰) and social functioning (the SF8⁷¹ or EQ5-D and the Personal Wellbeing Index⁷²), health service use, stigma, and violence and criminal justice (Table 1). The questionnaire for the SIRX-R Cohort will be a truncated version of the SuperMIX Cohort baseline questionnaire (questionnaires are available on request from the Principal Investigator).

| Table 1 SIRX-R & SuperMIX data domains | |
|--|---|
| Domain | Content example |
| Sociodemographics | Age, sex, gender identity, country of birth, ethnicity, indigenous identity, education and employment status, housing. |
| Substance use and treatment exposure | Drug type(s) used and injected, frequency of use and injecting, injecting initiation, current injecting behaviours, alcohol use, tobacco and e-cigarette use, substance use treatment. |
| Drug markets and purchasing | Cost and location of recent heroin and methamphetamine purchases. |
| MSIR visits | Frequency of visits, reasons for use, non-use, discontinuation of use. |
| MSIR on-site services | Frequency and type of on-site health and social service utilization, provision and uptake of referrals to other health and social services |
| Injecting-related harms | Overdose history, recent opioid overdose, recent methamphetamine overdose, injecting-related injuries and infections, blood borne viruses (including HIV/HCV treatment). |
| Health and well-being | General health conditions, women’s sexual and reproductive health, General Anxiety and Depression 7-item scale (GAD-7), reasons for health service access, EQ-5D, Patient Health Questionnaire (PHQ), |
| Other health service use | Use of other primary and specialist health services and reasons for use. |

| | |
|--------------------------------------|--|
| Stigma | Experience of stigma or discrimination related to drug use. |
| Violence and criminal justice | Violent victimisation, police contact, imprisonment history. |
| Trauma history | Experiences of child maltreatment and other psychological trauma |

Record linkage data

Record linkage to routinely collected administrative data sources to measure health service utilisation will occur over the study period, with participants also requested to consent for longer-term record linkage. Using the SuperMIX Cohort record linkage framework,¹⁶ participants will be asked to consent for linkage to databases capturing MSIR facility use, specialist and primary healthcare consultations, prescription medication dispensations, Victorian emergency and tertiary health service presentations, specialist drug treatment service contacts, criminal justice contacts, and death records. All databases are outlined in Table 2. Linkage will be undertaken by accredited linkage authorities following approval from all data custodians. Linked data are deidentified and will be stored in a secure data storage and analysis environment such as the Sax Institute's Secure Unified Research Environment (SURE).⁷³ All analysis outputs are reviewed by the Sax Institute for compliance with data custodian requirements to ensure participant privacy is maintained.

Table 2 Administrative databases for linkage

| Source Database | Description | Key variables |
|---|--|---|
| MSIR Client Database* | Records of all client visits to the MSIR. | Visit date and time to determine number of visits per person. |
| MSIR Medical Record* | Records all on-site health and social services | Medical comorbidity and on-site service provision |
| Medicare Benefits Schedule (MBS) | Records of all primary healthcare services provided through government subsidised program. | Service date, Medicare item number and description. |
| Pharmaceutical Benefits Scheme (PBS) | Records of all dispensations of medications available through the government-subsided program. | Date of dispensation, medication type. |
| Victorian Admitted Episodes Database (VAED) | Records of all admissions and separations from Victorian hospitals. | Admission date and time, separation date and time, primary and secondary diagnoses, treatment procedures. |
| Victorian Emergency Minimum Dataset (VEMD) | Records of all presentations to Victorian hospital emergency departments. | Arrival date and time, separation date and time, mode of arrival, triage category, primary and secondary diagnoses, departure status. |
| Victorian Ambulance Clinical Information System (VACIS) | Records of all patient care events attended to by Ambulance Victoria. | Arrive date and time, location, patient clinical indicators, case information, primary incident assessment, transport. |
| Victorian Public Mental Health Database | Records of all episodes of care delivered by Victorian public mental health services | Admission/contact date and time, separation date and time, crisis |

| | | |
|--|---|---|
| | including inpatient and community care. | assessment, primary and secondary diagnoses, patient legal status. |
| Victorian Drug and Alcohol Collection (VADC) | Specialist drug and alcohol treatment service contacts in Victoria. | Treatment start and end date, service type, client substance use. |
| Law Enforcement Assistance Program (LEAP) | Records of all contacts with Victoria Police. | Contact date and time, details of offence of reason for contact, outcome of police contact. |
| Corrections Victoria (CV) | All episodes of imprisonment in Victoria. | Prison reception and discharge dates. |
| National Death Index (NDI) | Mortality information for all deaths occurring in Australia. | Date and cause of death. |
| Note * These data will be used in exposure derivation. | | |

Measures

Outcomes

Derived from the legislated aims of the MSIR, the primary outcomes will be observed reductions in all-cause and drug-related mortality and ambulance attendances for non-fatal overdose. Secondary outcomes include reductions in drug-related hospitalisations such as injecting-related injuries and infections, and increased uptake of OAT (where indicated) and other non-acute health services.

Exposures

The primary exposure for the SIRX Study is time-varying frequency of SIF use. Participants will be categorised as frequent (\geq weekly) or infrequent ($<$ weekly) users of the MSIR based on facility utilisation rates determined from MSIR client database records, which will vary across time as people change their frequency of SIF use. For the SuperMIX Cohort, participants will also be able to be categorised as frequent ($\geq 50\%$ of their injections) or infrequent ($< 50\%$ of their injections) users of the MSIR facility on the basis of self-report questions currently implemented in the SuperMIX survey; which collects information on the proportion of injections that took place in the MSIR in the past month.⁷⁴ Analyses using this MSIR frequency threshold has been previously published.³⁸ Sensitivity analyses will be considered to explore the MSIR use thresholds. Non-MSIR controls will be SuperMIX Cohort participants who indicate they have not used the MSIR, which may change over time.

Statistical analyses

SIRX-R cohort

Mortality. We will undertake appropriate survival modelling (e.g. Cox regression or parametric [accelerated failure time or proportional hazards]) to estimate the association between MSIR use and mortality, taking account of factors that might confound the association. In these models MSIR use will be estimated as a time-varying exposure using person-period/episode split data. Prior use of the MSIR (before SIRX Study enrolment) will be considered when accounting for possible left truncation bias in these analyses. To provide more robust causal inference using data from the SIRX-

R Cohort, we will also explore application of a case-time-control method to provide fixed effects estimation implicitly controlling for all time-invariant measured and unmeasured confounders (e.g., prior overdose history, time since first injection, prior level of health care usage and treatment utilisation, general health at baseline, sex).⁷⁵ This statistical model will be implemented via an exposure/outcome reversed conditional logistic regression analysis on discrete-time participant-period data representing the follow-up durations for each participant (e.g., days), ending in either death or censorship.

Ambulance-attended non-fatal overdose. We will undertake generalised linear mixed modelling (GLMM, e.g. Poisson (with bootstrapped standard errors) or negative binomial) on person-period data (i.e., repeated ambulance-attended overdoses per participant measured periodically) to estimate the association between MSIR use and ambulance-attended non-fatal overdose. As stated for mortality analyses, we will implicitly control for all measured and unmeasured time-invariant confounders, a fixed-effects generalised linear modelling (Poisson or negative binomial) approach will be also explored using person-period data.

SuperMIX Cohort

Mortality and ambulance-attended non-fatal overdose. To estimate the total causal effect (also referred to as the average causal treatment effect) of participant MSIR use on mortality and ambulance-attended non-fatal overdose suitable causal inference statistical modelling (e.g., Marginal Structural Modelling⁷⁶ [MSM] or sequential conditional mean modelling⁷⁷ [SCMM]) will be undertaken on annual participant person-period data. In both these modelling methods and through different adjustment approaches (inverse probability weighting [IPW] for MSM and prior confounder/measure conditioning for SCMM possibly combined with IPWs to provide doubly robust estimation), time-independent and time-dependent confounding can be adjusted for to estimate total causal effects, without risk of introducing over-control bias (time-dependent confounding). We propose the application of MSM and/or SCMM given key differences between the methods in terms of levels of flexibility, bias and ease of implementation (i.e. handling missing data and dropout, exposure and covariate interactions, estimation for continuous exposures, covariate/confounder history imbalance across exposed and unexposed treatment groups and precision; all favouring SCMM) and the ability to estimate direct longer term (*not total*) causal effects if required (only possible with MSM). Generalised linear modelling and generalised estimating equations will be used to implement MSMs and SCMMs respectively, with the appropriate distributional assumptions and link functions applied given specific outcome measurement (event-history modelling for morbidity and non-normal repeated measures estimating equations for ambulance-attended non-fatal overdose). Data generating processes will be postulated using directed acyclic graphs, and these will inform the necessary structure of the statistical models to enable identification and estimation of total causal effects. Data generating processes will also help inform the application of regression modelling.

Missing data treatment and attrition

Depending on the specific analysis being undertaken, a range of missing data strategies will be considered in terms of missing data and attrition. For analyses which entail GLMM, maximum likelihood estimation will be used, and this provides unbiased effect estimates using all participant

observations assuming missingness due to attrition takes a missing-at-random (MAR) process (i.e. missingness can be not ‘missing-completely-at-random (MCAR) and can depend on model covariates and the outcomes themselves at prior occasions (incl. random intercepts). For MSMs, use of inverse probability treatment weights will incorporate a censoring weight component (based on covariates known to predict study drop-out). SCMMs produce unbiased estimates in the face of attrition when regression models include covariates known to predict study drop-out. Where there is considerable missing data on covariates in these analyses (e.g. >10%), either multiple imputation or where possible (GLMM, linear mixed modelling (LMM)) full information maximum likelihood (FIML, implemented in Mplus) will be used for unbiased (assuming MAR) missing data treatment. Finally, in all survival analyses, we will perform sensitivity analyses to estimate the extent to which right-censoring in the data (including attrition) is informative with respect to the participant’s hazard of the outcome (e.g. participants with a high hazard of non-fatal overdose may be more likely to be lost to follow up). Non-informative censoring is a key assumption of survival analysis.

Statistical Power

Table 3 below details the approximate minimum detectable differences for mortality and non-fatal overdose analyses based on the expected distribution of participants in each cohort. Monte Carlo simulation modelling (using Generalised linear mixed modelling [GLMM]) was used to estimate minimum detectable differences for non-fatal overdose and an exponential proportional hazards parametric survival model used for mortality. Baseline hazards (mortality: 1.1 per 100PY) and incidence rates (non-fatal overdose: 8.8 per 100PY) applying to each comparison were taken from current SuperMIX cohort data,⁷⁸ as were the means and variance components used for the longitudinal GLMM simulations. All effect size estimations assumed 80% power and 5% significance. For Monte Carlo simulated analyses (n=300 replications), simulations were based on three annual outcome measurements and expected cohort attrition (SuperMIX analyses) of 30% in year 1 and 25% thereafter.

| Table 3 Minimum detectable effect sizes for outcomes | | | |
|---|--|----------------|--------------------|
| SIRX Study | Comparison | Mortality (HR) | non-fatal OD (IRR) |
| SIRX-R Cohort | Frequent (weekly) vs. infrequent. (< weekly) use | 0.42 | 0.69 |
| SuperMIX Cohort | Frequent (≥ 50% all injections) vs. no use | 0.3 | 0.58 |
| SuperMIX Cohort | Infrequent (< 50% injections) vs. no use | 0.37 | 0.64 |
| Note: SIRX-R = Supervised Injecting Room Registration Cohort, SuperMIX = Melbourne Injecting Drug User Cohort, OD = overdose, HR = Hazard Ratio, IRR = Incidence Rate Ratio | | | |

Economic evaluation

Cost data will be available to enable economic modelling. Health economic outcomes will be considered from a government perspective, compared across the categories of MSIR exposure after

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

weighting for cohort size. The main outcomes will be (1) the difference in total annual costs; (2) the cost per life saved; and (3) the cost per quality-adjusted life year (QALY) gained. Total costs will include costs associated with MSIR use (calculated from financial documentation and budgets over time), costs of ambulance callouts for overdoses (available on Ambulance Victoria website), healthcare costs (matching linked healthcare usage data with corresponding MBS/PBS codes, in particular costs associated with managing blood borne virus or injecting related injuries), and OAT treatment costs. QALY gains will be estimated based on additional OAT uptake, treatment of comorbidities (e.g. person-years lived with hepatitis C), changes in employment, and deaths averted that are attributable to the MSIR. Cost per QALY gained outcomes will enable benchmarking of the MSIR against other health interventions.

Patient and public involvement

The SIRX Study was designed in partnership with key stakeholders including Harm Reduction Victoria, the representative body for people who use and inject drugs in Victoria; North Richmond Community Health, the primary health service operating the Melbourne MSIR; cohealth, a not-for-profit community health organisation providing health services including services and support for alcohol and other drugs; and the Victorian State Government. These stakeholders, along with study investigators, contribute to ongoing oversight of the study via their involvement in the SIRX Study Research Advisory group.

Discussion

The SIRX Study has been designed to provide new evidence on the effects of SIFs in reducing overdose deaths and drug-related harms within the Australian context. Previous research has highlighted the benefits of the Melbourne MSIR, but is limited by short evaluation timeframes, reliance on ecological data, or the absence of temporality to control for confounding and determine causation.^{38, 50, 58} Drawing on the cohort methodology used to evaluate the Insite SIF in Canada,⁶⁶ our study aims to generate quantitative evidence of the impact of the MSIR including its model of on-site health and social service delivery, overcoming the limitations described above. The results can be used to inform decisions about the value of SIFs in general, and the specific value of a model embedding the SIF within a range of on-site health and social services.

Limitations

The SIRX study, while valuable in measuring the effects of Melbourne's MSIRs in reducing drug-related harm, is subject to several limitations. Self-report data may be subject to response biases, including recall and socially desirable responding. The SuperMIX Cohort component may be subject to lost-to-follow-up; previous work demonstrated stable attrition in the SuperMIX Cohort with higher attrition among individuals with greater risk profiles.⁷⁹ However, using linked data for primary outcomes mitigates the risk of such biases. Despite the large projected sample size, the expected effect estimates for mortality remain relatively imprecise in contrast to the effects on non-fatal overdose. As with all observational studies, confounding may impact the observed associations, but causal inference methods are being applied to minimise this. Finally, selection bias may mean the study is not representative of all Melbourne MSIR clients and findings may not be generalisable to other SIFs. However, the use of comprehensive time-dependent data collected across a range of

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

individual and health-related factors, combined with the use of casual inference methods, means the SIRX Study will generate strong evidence on the causal effects of SIFs.

For peer review only

Enseignement Supérieur (ABES) .
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Ethics and dissemination

Ethics approval

SuperMIX Study (599/21) and SIRX-R Study (71/23) ethics approvals were obtained from Alfred Hospital Research Ethics Committee. Participants will be assessed for capacity to provide informed consent following a detailed explanation of the study. Participants are informed of their right to withdraw from the study at any time and that withdrawing does not impact their access to services.

Results dissemination

Aggregated research results will be disseminated via presentations at national and international scientific conferences and publications in peer-reviewed journals. Local-level reports and outputs will be distributed to key study stakeholders and policymakers. Summary findings for participants will be displayed in relevant services and the study van, via accessible outputs (e.g., short infographics summaries).

Acknowledgements

We acknowledge the contribution of SuperMIX and SIRX-R participants, the Burnet Institute fieldwork team, staff at the Melbourne Supervised Injecting Room, and supporting community services and organizations.

Funding

The SIRX study is funded by an NHMRC Partnership Projects grant (#2019034). Baseline data collection for SuperMIX was funded by the Colonial Foundation Trust and the NHMRC (#545891, #1126090), with ongoing data collection funded by an NHMRC Clinical Trials and Cohort Studies grant (#2023690). The authors gratefully acknowledge the support of the Victorian Operational Infrastructure Fund. The funders had no input into the work.

Author contributions

The study concept and design was conceived by PD, PH, AR, NS, TK, DO, PA, AT, NC, LM, MS, and MH. PD, AS, PH, DVH, ZL and MH assisted in refining the study questionnaires and study protocols. AS leads the study coordination and implementation. DVH and ZL are leading data collection. Analyses will be conducted by PA, NS and JS. SC and JN provide key stakeholder input and guidance. AS, MH and PD prepared the first draft of the manuscript. All authors critically revised the manuscript and approved the submitted version. Paul Dietze is the guarantor

Data statement

Data for the SIRX Study are securely housed on the Burnet Institute server and an accredited secure research environment as per the requirements of relevant data custodians. Only researchers with ethics approval will have access to data. Requests for access to datasets generated for the SIRX study should be made to the corresponding author or Principal Investigator (PD).

References

1. Larney S, Peacock A, Leung J, Colledge S, Hickman M, Vickerman P, et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. *Lancet Glob Health*. 2017;5(12):e1208-e20.

2. Mathers BM, Degenhardt L, Bucello C, Lemon J, Wiessing L, Hickman M. Mortality among people who inject drugs: a systematic review and meta-analysis. *Bull World Health Organ*. 2013;91(2):102-23.

3. Chrzanowska A, Man N, Akhurst J, Sutherland R, Degenhardt L, Peacock A. Trends in overdose and other drug-induced deaths in Australia, 2002-2021. Sydney: National Drug and Alcohol Research Centre, UNSW Sydney; 2023.

4. Degenhardt L, Webb P, Colledge-Frisby S, Ireland J, Wheeler A, Ottaviano S, et al. Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic review. *Lancet Glob Health*. 2023;11(5):e659-e72.

5. Tait R, Allsop S, eds. Quantifying the Social Costs of Pharmaceutical Opioid Misuse & Illicit Opioid Use to Australia in 2015/16. Perth, Western Australia: NDRI; 2020.

6. Whetton S, Shanahan M, Cartwright K, Duraisingam V, Ferrante A, Gray D, et al. The Social Costs of Methamphetamine in Australia 2013/14. Perth, WA; 2016.

7. Kirwan A, Quinn B, Winter R, Kinner SA, Dietze P, Stoovn M. Correlates of property crime in a cohort of recently released prisoners with a history of injecting drug use. *Harm Reduction Journal*. 2015;12(1).

8. Nambiar D, Spelman T, Stoové M, Dietze P. Are People Who Inject Drugs Frequent Users of Emergency Department Services? A Cohort Study (2008–2013). *Substance use & misuse*. 2018;53(3):457-65.

9. Nambiar D, Stoové M, Hickman M, Dietze P. A prospective cohort study of hospital separations among people who inject drugs in Australia: 2008–2013. *BMJ Open*. 2017;7(8).

10. Maher L, Dixon TC. Collateral damage and the criminalisation of drug use. *The Lancet HIV*. 2017;4(8):e326-e7.

11. Darke S, Torok M. Childhood physical abuse, non-suicidal self-harm and attempted suicide amongst regular injecting drug users. *Drug Alcohol Depend*. 2013;133(2):420-6.

12. Darke S, Torok M. The association of childhood physical abuse with the onset and extent of drug use among regular injecting drug users. *Addiction*. 2014;109(4):610-6.

13. Richardson L, Wood E, Kerr T. The impact of social, structural and physical environmental factors on transitions into employment among people who inject drugs. *Soc Sci Med*. 2013;76(1):126-33.

14. Topp L, Iversen J, Baldry E, Maher L, Collaboration of Australian N. Housing instability among people who inject drugs: results from the Australian needle and syringe program survey. *Journal of urban health : bulletin of the New York Academy of Medicine*. 2013;90(4):699-716.

15. Arum C, Fraser H, Artenie AA, Bivegete S, Trickey A, Alary M, et al. Homelessness, unstable housing, and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. *The Lancet Public Health*. 2021.

16. Van Den Boom W, Quiroga MDM, O'Keefe D, Kumar D, Hill PL, Scott N, et al. Cohort Profile: The Melbourne Injecting Drug User Cohort Study (SuperMIX). *International journal of epidemiology*. 2021.

17. Winter RJ, Stoove M, Agius PA, Hellard ME, Kinner SA. Injecting drug use is an independent risk factor for reincarceration after release from prison: A prospective cohort study. *Drug Alcohol Rev*. 2019;38(3):254-63.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

18. Dolan K, Wirtz AL, Moazen B, Ndeffo-Mbah M, Galvani A, Kinner SA, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. *The Lancet*. 2016;388(10049):1089-102.
19. Aldridge RW, Story A, Hwang SW, Nordentoft M, Luchenski SA, Hartwell G, et al. Morbidity and mortality in homeless individuals, prisoners, sex workers, and individuals with substance use disorders in high-income countries: a systematic review and meta-analysis. *The Lancet*. 2018;391(10117):241-50.
20. Tsai AC, Kiang MV, Barnett ML, Beletsky L, Keyes KM, McGinty EE, et al. Stigma as a fundamental hindrance to the United States opioid overdose crisis response. *PLOS Medicine*. 2019;16(11):e1002969.
21. Nambiar D, Stooze M, Dietze P. Frequent emergency department presentations among people who inject drugs: A record linkage study.(Report). *International Journal of Drug Policy*. 2017;44:115.
22. Fernandes RM, Cary M, Duarte G, Jesus G, Alarcão J, Torre C, et al. Effectiveness of needle and syringe programmes in people who inject drugs - An overview of systematic reviews. *BMC Public Health*. 2017;17(1):309.
23. Curtis M, Wilkinson AL, Dietze P, Stewart AC, Kinner SA, Winter RJ, et al. Is use of opioid agonist treatment associated with broader primary healthcare use among men with recent injecting drug use histories following release from prison? A prospective cohort study. *Harm Reduction Journal*. 2023;20(1):42.
24. Colledge-Frisby S, Ottaviano S, Webb P, Grebely J, Wheeler A, Cunningham EB, et al. Global coverage of interventions to prevent and manage drug-related harms among people who inject drugs: a systematic review. *Lancet Glob Health*. 2023;11(5):e673-e83.
25. European Monitoring Centre for Drugs and Drug Addiction. Perspectives on drugs - Drug consumption rooms: an overview of provision and evidence. EMCDDA; 2018.
26. Kerr T, Wood E, Montaner J, Tyndall M. Findings from the evaluation of Vancouver's pilot medically supervised safer injection facility—Insite (UHRI Report). Vancouver, BC: BC Centre for Excellence in HIV/AIDS: Addiction and Urban Health Research Initiative; 2009.
27. Small W, Wood E, Lloyd-Smith E, Tyndall M, Kerr T. Accessing care for injection-related infections through a medically supervised injecting facility: a qualitative study. *Drug Alcohol Depend*. 2008;98(1-2):159-62.
28. Milloy MJS, Kerr T, Tyndall M, Montaner J, Wood E. Estimated Drug Overdose Deaths Averted by North America's First Medically-Supervised Safer Injection Facility. *PLOS ONE*. 2008;3(10):e3351.
29. Jozaghi E, Reid AA. The Potential Role for Supervised Injection Facilities in Canada's Largest City, Toronto. *International Criminal Justice Review*. 2015;25(3):233-46.
30. Kennedy MC, Hayashi K, Milloy MJ, Wood E, Kerr T. Supervised injection facility use and all-cause mortality among people who inject drugs in Vancouver, Canada: A cohort study. *PLoS Med*. 2019;16(11):e1002964.
31. Salmon AM, van Beek I, Amin J, Kaldor J, Maher L. The impact of a supervised injecting facility on ambulance call-outs in Sydney, Australia. *Addiction*. 2010;105(4):676-83.
32. Lambdin BH, Davidson PJ, Browne EN, Suen LW, Wenger LD, Kral AH. Reduced Emergency Department Visits and Hospitalisation with Use of an Unsanctioned Safe Consumption Site for Injection Drug Use in the United States. *Journal of General Internal Medicine*. 2022;37(15):3853-60.
33. Roux P, Jauffret-Roustide M, Donadille C, Briand Madrid L, Denis C, Célérier I, et al. Impact of drug consumption rooms on non-fatal overdoses, abscesses and emergency department visits in people who inject drugs in France: results from the COSINUS cohort. *International journal of epidemiology*. 2023;52(2):562-76.
34. Kennedy MC, Hayashi K, Milloy MJ, Boyd J, Wood E, Kerr T. Supervised injection facility use and exposure to violence among a cohort of people who inject drugs: A gender-based analysis. *Int J Drug Policy*. 2020;78:102692.

35. Fairbairn N, Small W, Shannon K, Wood E, Kerr T. Seeking refuge from violence in street-based drug scenes: Women's experiences in North America's first supervised injection facility. *Social Science & Medicine*. 2008;67(5):817-23.

36. Kerr T, Tyndall M, Li K, Montaner J, Wood E. Safer injection facility use and syringe sharing in injection drug users. *Lancet*. 2005;366(9482):316-8.

37. Pinkerton SD. How many HIV infections are prevented by Vancouver Canada's supervised injection facility? *Int J Drug Policy*. 2011;22(3):179-83.

38. Van Den Boom W, del Mar Quiroga M, Fetene DM, Agius PA, Higgs PG, Maher L, et al. The Melbourne Safe Injecting Room Attracted People Most in Need of Its Service. *Am J Prev Med*. 2021;61(2):217-24.

39. Reddon H, Wood E, Tyndall M, Lai C, Hogg R, Montaner J, et al. Use of North America's first medically supervised safer injecting facility among HIV-positive injection drug users. *AIDS education and prevention : official publication of the International Society for AIDS Education*. 2011;23(5):412-22.

40. Wood E, Tyndall MW, Li K, Lloyd-Smith E, Small W, Montaner JSG, et al. Do Supervised Injecting Facilities Attract Higher-Risk Injection Drug Users? *American Journal of Preventive Medicine*. 2005;29(2):126-30.

41. Wood E, Kerr T, Small W, Li K, Marsh DC, Montaner JSG, et al. Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users. *CMAJ*. 2004;171(7):731-4.

42. Salmon AM, Thein HH, Kimber J, Kaldor JM, Maher L. Five years on: what are the community perceptions of drug-related public amenity following the establishment of the Sydney Medically Supervised Injecting Centre? *Int J Drug Policy*. 2007;18(1):46-53.

43. Maher L, Salmon A. Supervised injecting facilities: how much evidence is enough? *Drug Alcohol Rev*. 2007;26(4):351-3.

44. Christie T, Wood E, Schechter MT, O'Shaughnessy MV. A comparison of the new Federal Guidelines regulating supervised injection site research in Canada and the Tri-Council Policy Statement on Ethical Conduct for Research Involving Human Subjects. *International Journal of Drug Policy*. 2004;15(1):66-73.

45. Levengood TW, Yoon GH, Davoust MJ, Ogden SN, Marshall BDL, Cahill SR, et al. Supervised Injection Facilities as Harm Reduction: A Systematic Review. *Am J Prev Med*. 2021;61(5):738-49.

46. Kerr T, Mitra S, Kennedy MC, McNeil R. Supervised injection facilities in Canada: past, present, and future. *Harm Reduction Journal*. 2017;14(1):28.

47. Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. *The Lancet Global Health*. 2017;5(12):e1192-e207.

48. Iversen J, Wand H, Topp L, Kaldor J, Maher L. Extremely low and sustained HIV incidence among people who inject drugs in a setting of harm reduction. *AIDS*. 2014;28(2):275-8.

49. Dwyer R, Power R, Denham G, Dietze P. Public injecting and public amenity in an inner-city suburb of Melbourne, Australia. *Journal of Substance Use*. 2014:1-8.

50. MSIR Review Panel. Review of the MSIR. Melbourne. Victoria: State Government of Victoria; 2020.

51. Hawkins J. Finding into death without inquest. Melbourne: Victorian Coroner; 2021. p. 1-25.

52. Clark N. The role of a medically supervised injecting room in improving access to health and social services. *Lisbon Addictions; Lisbon, Portugal*. 2022.

53. MacIsaac MB, Whitton B, Anderson J, Cogger S, Vella-Horne D, Penn M, et al. Point-of-care HCV RNA testing improves hepatitis C testing rates and allows rapid treatment initiation among people who inject drugs attending a medically supervised injecting facility. *Int J Drug Policy*. 2024;125:104317.

54. MacIsaac MB, Whitton B, Hubble A, Cogger S, Penn M, Weeks A, et al. Eliminating hepatitis C in Australia: a novel model of hepatitis C testing and treatment for people who inject drugs at a medically supervised injecting facility. *Med J Aust.* 2023;218(6):256-61.
55. Weeks A, Cogger S, Clark N. Initial experience with subcutaneous depot buprenorphine in a medically supervised injecting facility. *Drug Alcohol Rev.* 2021;40(7):1354-5.
56. North Richmond Community Health. Medically Supervised Injecting Room: NRCH; 2024 [Available from: <https://nrch.com.au/services/medically-supervised-injecting-room/>].
57. Whiteside B, Dunn M. Voices represented and voices silenced: Represented voices in the media coverage of the implementation of a supervised injecting facility. *The International journal of drug policy.* 2023;121:104213-.
58. MSIR Review Panel. Review of the Medically Supervised Injecting Room. Melbourne; 2023.
59. ABC News. Safe injecting room trial extended in North Richmond, new facility slated for near Queen Victoria Market in Melbourne CBD. ABC News. 2020.
60. Livingston JD. Supervised consumption sites and crime: scrutinizing the methodological weaknesses and aberrant results of a government report in Alberta, Canada. *Harm Reduction Journal.* 2021;18(1):4.
61. Liang J, Alexeev S. Harm reduction or amplification? The adverse impact of a supervised injection room on housing prices. *Regional Science and Urban Economics.* 2023;98:103856.
62. Whiteside B, Dunn M. The print media's construction of the 'drug problem' in Victorian newspapers: The case of North Richmond Community Health's medically supervised injecting room. *Drug and alcohol review.* 2022;41(4):818-29.
63. Hall B. Flare up as CBD building shortlisted for injecting room site. *The Age.* 2023.
64. Willingham R, Rollason B. Victorian government scraps plans for a second supervised injecting room in Melbourne. ABC News. 2024.
65. Carey A, Dow A. Victorian Liberals to shut down injecting room in a week if elected. *The Age.* 2018.
66. Wood E, Kerr T, Lloyd-Smith E, Buchner C, Marsh DC, Montaner JSG, et al. Methodology for evaluating Insite: Canada's first medically supervised safer injection facility for injection drug users. *Harm Reduction Journal.* 2004;1(1):9.
67. Horyniak D, Higgs P, Jenkinson R, Degenhardt L, Stoové M, Kerr T, et al. Establishing the Melbourne injecting drug user cohort study (MIX): rationale, methods, and baseline and twelve-month follow-up results. *Harm Reduction Journal.* 2013;10(1):11.
68. MacIsaac M, Whitton B, Anderson J, al. e. Rapid point-of-care hepatitis C testing in a medically supervised injecting room. *EASL Congress; 23-26 June 2021*2021.
69. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: Building an international community of software platform partners. *J Biomed Inform.* 2019;95:103208.
70. Kroenke KMD, Spitzer RLMD, Williams JBWDSW, Löwe BMDPD. The Patient Health Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: a systematic review. *General hospital psychiatry.* 2010;32(4):345-59.
71. Ware JE, Kosinski M, Dewey JE, Gandek B. How to Score and Interpret Single-Item Health Status Measures: A Manual for Users of the SF-8 Health Survey (With a Supplement on the SF-6 Health Survey). Lincoln, Rhode Island: QualityMetric Incorporated; 2001.
72. International Wellbeing Group. PWI. Melbourne: Australian Centre on Quality of Life; 2006.
73. Sax Institute. Secure Unified Research Environment (SURE). Sax Institute; 2024.
74. Artenie A, Stone J, Fraser H, Stewart D, Arum C, Lim AG, et al. Incidence of HIV and hepatitis C virus among people who inject drugs, and associations with age and sex or gender: a global systematic review and meta-analysis. *The Lancet Gastroenterology & Hepatology.* 2023;8(6):533-52.
75. Suissa S. The Case-Time-Control Design. *Epidemiology (Cambridge, Mass).* 1995;6(3):248-53.
76. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. *Epidemiology.* 2000;11(5):550-60.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

77. Keogh RH, Daniel RM, VanderWeele TJ, Vansteelandt S. Analysis of Longitudinal Studies With Repeated Outcome Measures: Adjusting for Time-Dependent Confounding Using Conventional Methods. *Am J Epidemiol.* 2018;187(5):1085-92.

78. Hill PL, Stoové M, Agius PA, Maher L, Hickman M, Crawford S, et al. Mortality in the SuperMIX cohort of people who inject drugs in Melbourne, Australia: a prospective observational study. *Addiction.* 2022;117(12):3091-8.

79. Abdelsalam S, Agius PA, Sacks-Davis R, Roxburgh A, Livingston M, Maher L, et al. Characteristics of attrition within the SuperMIX cohort of people who inject drugs: A multiple event discrete-time survival analysis. preprint. 2024.

For peer review only

Enseignement Supérieur (ABES) :
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Figure legend

Figure 1 Study design of the SIRX Study

For peer review only




Figure 1 Study design of the SIRX Study

Figure 1. Study design of the SIRX study

160x87mm (300 x 300 DPI)